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Per and polyfluoroalkyl substances (PFAS) are a group of chemicals that have been widely 
used in industrial and consumer products for decades. Recent estimates suggest there are over 4000 
PFAS on the global market. However, many of these have very little information available about 
their potential hazards. Given the vast number of PFAS, a three-level hierarchical framework that 
includes permeability-limited physiologically based toxicokinetic (PBTK) model, molecular 
dynamics (MD) based workflow and machine learning (ML) based quantitative structure-activity 
relationships (QSAR) was proposed to inform the toxicokinetics, bioaccumulation and toxicity of 
PFAS. The PBTK model was developed to estimate the toxicokinetic and tissue distribution of 
perfluorooctanoic acid (PFOA) in male rats; the hierarchical Bayesian analysis was used to reduce 
the uncertainty of parameters and improve the robustness of the PBTK model. By comparing with 
different experimental studies, most of the predicted plasma toxicokinetic (e.g., half-life) and 
tissue distribution fell well within a factor of 2.0 of the measured data. 
Moreover, a modeling workflow that combines molecular docking and MD simulation 
techniques was developed to estimate the binding affinity of PFAS for liver-type fatty acid binding 
protein (LFABP). The results suggest that EEA and ADONA are at least as strongly bound to rat 
LFABP as perfluoroheptanoic acid (PFHpA), and to human LFABP as PFOA; both F-53 and F-
53B have similar or stronger binding affinities than perfluorooctane sulfonate (PFOS). In addition, 
human, rat, chicken, and rainbow trout had similar binding affinities to one another for each tested 
 v 
PFAS, whereas Japanese medaka and fathead minnow had significantly weaker LFABP binding 
affinity for some PFAS.  
Finally, the ML-based QSAR model was developed to predict the bioactivity of around 
4000 PFAS from the OECD report. Based on the collected PFAS dataset, a total of 5 different 
machine learning models were trained and validated that cover a variety of conventional models 
(i.e., logistic regression, random forest and multitask neural network) and advanced graph-based 
models (i.e., graph convolutional network and weave model). The model indicated that most of 
the biologically active PFAS have perfluoroalkyl chain lengths less than 12 and are categorized 
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1.0 Dissertation Introduction 
1.1 Motivation 
1.1.1 PFAS as Emerging Contaminants 
 
Figure 1. Example of PFAS structures. 
 
Per- and polyfluoroalkyl substances (PFAS, CnF2n+1-R) are a diverse group of chemicals 
that have been widely used in a variety of industrial and consumer products, from fire-fighting 
foams to food contact materials to apparel.1-6 Based on a recent Organization for Economic 
Cooperation and Development (OECD) report, there are 4730 PFAS that have been in some way 
registered and/or produced since the late 1940s.7 Some of their chemical structures are indicated 
in Figure 1; broadly, those chemicals can be divided into perfluoroalkyl acids (PFAA, e.g., 
perfluoroalkyl carboxylic acids), PFAA precursors (e.g., fluorotelomer-based substances) and 
others (e.g., fluoropolymers).8 Due to the strength of the carbon-fluorine bond, fully fluorinated 
PFAS, such as perfluoroalkyl carboxylic acids (PFCA) and perfluoroalkane sulfonic acids (PFSA), 
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are extremely persistent in the environment and hard to remove, while other PFAS with partially 
fluorinated structures, such as fluorotelomer alcohols, usually break down to form more persistent, 
fully fluorinated PFAS.9 As a result, those PFAS have been detected ubiquitously in the 
environment, wildlife and in humans.10  
Moreover, unlike other persistent organic pollutants, many PFAS are acids that are almost 
fully ionized at environmentally relevant pH.11 Instead of passively accumulating in fat tissue, 
those chemicals interact with different kinds of proteins such as serum albumin and membrane 
transporters, which results in tissue-specific accumulation patterns.12 Experimental studies have 
found that many long-chain PFAA (defined as PFCAs with ≥7 perfluorinated carbons and PFSAs 
with ≥6 perfluorinated carbons) like perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic 
acid (PFOS) mainly accumulate in blood, liver and kidneys,13 and their biological half-lives were 
estimated to be several years for humans.14 Finally, toxicological studies in animals have shown 
that exposure to long-chain PFAS and short-chain PFAS (in higher concentrations) cause toxic 
effects on reproduction and development, and on the nervous, endocrine, and immune systems, 
among others.15-23  
The unique properties of PFAS and concerns about their persistence, bioaccumulation and 
toxicity have led to a phase-out of the production of long-chain PFAAs for the majority of uses.24, 
25 As a result, manufacturers have started using replacement substances that include shorter-chain 
homologues of PFOA and PFOS, as well as perfluoroether carboxylic acids (PFECAs) and 
perfluoroether sulfonic acids (PFESAs).25, 26 However, to date little information is disclosed about 
the identity and frequency of use of those alternative PFAS, let alone their potential hazards such 
as bioaccumulation potential and toxicity.26 Given the large number of PFAS, the scarce 
knowledge about their potential risks and the lack of effective control measures to eliminate them 
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from the environment, PFAS are considered a potentially intractable, never-ending chemicals 
management issue that challenges society.8 
1.1.2 Paradigm Shift in Toxicology 
The field of toxicology is undergoing a paradigm shift from primarily in vivo animal studies 
to in vitro assays and sophisticated modeling approaches for toxicity assessments.27, 28 The current 
risk assessment system, which relies on whole-animal-based toxicity-testing approaches for hazard 
identification and dose-response assessment, suffers from important limitations. Traditional 
toxicity testing methods are expensive, time-consuming, and use many laboratory animals, which 
limit their application for risk assessment of large numbers of chemicals like PFAS.27 Moreover, 
they provide little insight into the modes of action that are important for interpreting interspecies 
differences in toxicity and little information for assessing variation among individuals in specific 
susceptible groups.27 Alternative approaches to in vivo animal testing are needed for risk 
assessment of environmental contaminants.  
1.2 Objective 
Given the large number of PFAS (nearly 5000 7) and our limited resources (e.g., time and 
cost), it is not feasible to evaluate all PFAS individually through experiments. Therefore, in silico 
methods based on computational biology hold great promise for the hazard and risk assessment of 
those PFAS. As part of the efforts to tackle PFAS management issues and a response to the 
paradigm shift in toxicology, this dissertation focused on the development of reliable and efficient 
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in silico tools to predict the toxicokinetics, bioaccumulation and toxicity of PFAS. Specifically, 
the objectives of this project include: 
(1) Development of mechanistic physiologically based toxicokinetic (PBTK) models 
that aim at providing a quantitative simulation of the toxicokinetics and tissue distributions 
of PFAS in mammals. PBTK modeling is a promising tool to inform risk assessment of chemicals 
like PFAS.29 With appropriate specification of species- and chemical-specific parameters, PBTK 
models simulate absorption, distribution, metabolism, and excretion (ADME) of compounds in 
animals and humans, providing a useful tool to understand and extrapolate toxicokinetics across 
different species and dosing scenarios.29 Although PBTK models have been developed for PFAS 
in humans, rats and monkeys,30-36 none of these models explicitly take multiple protein-PFAS 
interactions into account. In addition, existing models use in vivo test data to fit many of their 
parameters, and thus the predictive power of these models largely relies on the quality of available 
in vivo data. When the training set is poor, predictions of traditional PBTK models are not 
satisfactory.34 To overcome these problems, we developed mechanistic PBTK models that 
explicitly consider protein-PFAS interactions and rely on no in vivo test data for parameterization 
(other than data on organism physiology compiled from the literature). PFAS-related parameters 
are instead obtained from in vitro studies or in silico predictions, and then used to predict in vivo 
toxicokinetics. These mechanistic PBTK models are intended to provide an effective framework 
to conduct in vitro-in vivo and in silico-in vivo extrapolation.  
(2) Development of a molecular dynamics (MD) based workflow that provides reliable 
and efficient estimation of protein-PFAS binding affinity. While many protein-PFAS 
interaction parameters are required to build the PBTK model, those data are very limited, 
especially for many untested PFAS. One way to obtain these parameters is by conducting in vitro 
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experiments. For example, a number of techniques such as fluorescence spectroscopy37, 
equilibrium dialysis38, and NMR39 have been widely used in recent years to measure protein 
binding affinity. The kinetics of PFAS uptake or efflux facilitated by transporters can also be 
obtained from cell-based in vitro assays, by incubation under a range of test compound 
concentrations40-42. However, chemical standards for the majority of those untested PFAS are still 
not widely available, limiting our ability to investigate protein-PFAS interactions experimentally. 
Here a computational approach that combines molecular dynamics (MD) and molecular docking 
is proposed for prediction of protein-PFAS interactions in a reliable and relatively efficient way, 
requiring only information on the three-dimensional structure of PFAS and target proteins.  
(3) Development of machine learning (ML)-based quantitative structure-activity 
relationships (QSAR) to predict the bioactivity of PFAS for screening purposes. Although the 
MD approach is a solid method to estimate protein-PFAS binding affinity, it is still too 
computationally expensive to handle the large PFAS dataset containing over 4000 chemicals, 
especially when the size of the protein of interest is large (e.g., serum albumin with molecular 
weight of around 65000 Daltons) — in such cases, the time it takes to run simulations and calculate 
free energies of binding are much longer (on the order of days per protein-PFAS pair).43, 44 To 
solve this problem, we applied much more cost-effective ML-based QSAR techniques that are able 
to screen a large number of chemicals based on their bioactivity prediction results. ML-based 
QSAR modeling is a data-driven approach that applies ML algorithms to model the relationship 
between physical and biological properties of compounds and their chemical structures.45 It is very 
cost-effective and therefore optimal for dealing with large datasets, and it has been successfully 
applied for decades in many areas like drug discovery and chemical toxicity predictions.46, 47 In 
this project, we build QSAR models to predict the bioactivity for a large number of PFAS. 
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Figure 2. Three-level hierarchical framework for PFAS assessment. 
 
As shown in Figure 2, the QSAR models, MD-based approach, and PBTK models form a 
three-level hierarchical framework to tackle the PFAS management issue. The bottom level is the 
ML-based QSAR model. As a statistical method, the QSAR cannot provide insights into the 
toxicokinetics for PFAS in biological system, Therefore, this level is mainly used for high-
throughput screening and prioritization for the large PFAS collection. The intermediate level is the 
MD-based approach to calculate protein-PFAS binding affinity. The protein-PFAS interaction 
results generated at this level can be used as parameters for the PBTK models in the top level. On 
the top level, the PBTK model is used to predict the toxicokinetics and bioaccumulation of the 
prioritized PFAS in biological systems. Since our PBTK modeling takes protein-PFAS interactions 
into consideration, it can be used to identify the proteins that play critical roles in potential PFAS 
bioaccumulation and toxicity. Unlike ML-based QSAR, the PBTK model can provide insight into 
the behavior of PFAS in different tissues of the biological system and integrate this distribution 
into a whole-organism picture of the biological fate of PFAS. 
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1.3 Organization 
The dissertation is organized as follows: 
In Chapter 2.0, the permeability-limited PBTK model that was developed to estimate the 
toxicokinetics and tissue distribution of PFOA in male rats is presented. The model explicitly 
considered multiple protein-PFAS interactions including the cellular uptake and efflux of PFOA 
via transporters and the protein binding of PFOA in different tissues. In addition, rather than 
requiring in vivo data fitting, all PFOA-related parameters in our model were obtained from in 
vitro studies. Finally, the hierarchical Bayesian framework with Markov chain Monte 
Carlo (MCMC) was employed to reduce the uncertainty of parameters and improve the robustness 
of the PBTK model. The model performance was evaluated by comparing its predictions with 
experimental data from three different studies.  
In Chapter 3.0, the molecular modeling workflow that combines molecular docking and 
molecular dynamics simulation techniques was developed to predict the protein binding affinity 
for PFAS in a reliable and relatively efficient way. To demonstrate the power of the workflow, the 
interactions between a total of 15 legacy and replacement PFAS (i.e., PFBA, PFPA, PFHxA, 
PFHpA, PFOA, PFNA, 2m-PFOA, PFBS, PFHxS, PFOS, ADONA, GenX, EEA, F-53 and F-53B) 
and 2 well-studied liver-type fatty acid binding proteins (LFABP) (i.e., rat and human LFABP) 
were tested to inform the bioaccumulation potential for novel PFAS. Moreover, the model was 
employed to probe the bioaccumulation potential across different species by examining LFABP 
interactions across 7 different species (i.e., human, rat, chicken, zebrafish, rainbow trout, fathead 
minnow, and Japanese medaka) for 9 PFAS (i.e., PFBA, PFPA, PFHxA, PFHpA, PFOA, PFNA, 
PFBS, PFHxS, and PFOS). The model prediction results were evaluated by comparing with 
experimental data extracted from three different studies. An approach that can predict PFAS 
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impacts across different species can be used both to inform ecosystem protection (e.g. to identify 
most vulnerable wildlife species) and to identify appropriate model species for human toxicity 
studies. 
In Chapter 4.0, a machine-learning-based quantitative structure-activity relationship 
(QSAR) model was developed to predict the bioactivity of around 4000 PFAS structures originally 
reported by the Organization for Economic Cooperation and Development (OECD) in 2018. By 
examining a number of available experimental data sets on chemical bioactivity, the first PFAS-
specific database was constructed that contains bioactivity information for 1012 PFAS from 26 
bioassays. Based on the collected PFAS dataset, a total of 5 different machine learning models 
were trained and validated that cover a variety of conventional models (i.e., logistic regression, 
random forest and multitask neural network) and advanced graph-based models (i.e., graph 
convolutional network and weave model). 
Finally, in Chapter 5.0, the key results in the dissertation are summarized, the significance 




2.0 Development of a Permeability-Limited Physiologically Based Toxicokinetic (PBTK) 
Model for Perfluorooctanoic Acid (PFOA) in Male Rats 
This chapter is reproduced in part with permission from: 
Cheng, W. and Ng, C. A. A permeability-limited physiologically based pharmacokinetic 
(PBPK) model for perfluorooctanoic acid (PFOA) in male rats. Environmental Science & 
Technology 2017, 51 (17), 9930-9939. Copyright 2017 American Chemical Society. 
[https://pubs.acs.org/doi/abs/10.1021/acs.est.7b02602] 
and 
Cheng, W. and Ng, C. A. Bayesian refinement of a permeability-limited physiologically 
based pharmacokinetic (PBPK) model for perfluorooctanoic acid (PFOA) in male rats. Chemical 
Research in Toxicology, submitted for publication. Unpublished work copyright 2021 American 
Chemical Society. 
 
Physiologically based toxicokinetic (PBTK) modeling is a powerful in silico tool that can 
be used to simulate the toxicokinetics and tissue distribution of xenobiotic substances, such as 
perfluorooctanoic acid (PFOA) in organisms. However, most existing PBTK models have been 
based on the flow-limited assumption. Given the large molecular weight and high extent of 
ionization of PFOA, we develop a permeability-limited PBTK model to estimate the toxicokinetics 
and tissue distribution of PFOA in male rats. Our model considers the uptake and efflux of PFOA 
via both passive diffusion and active transport facilitated by various transporters, association with 
serum albumin in circulatory and extracellular spaces, and association with intracellular proteins 
in liver and kidney. In addition, hierarchical Bayesian framework with Markov chain Monte 
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Carlo (MCMC) was employed to reduce the uncertainty of parameters and improve the robustness 
of the PBTK model. With the optimized posterior parameters, the PBTK model was evaluated by 
comparing its prediction with experimental data from three different studies. The results show that 
the uncertainties of the posterior model parameters were reduced substantially. Moreover, the 
PBTK model became more robust: with the posterior parameters, most of the predicted plasma 
toxicokinetic (e.g., half-life) and tissue distribution fell well within a factor of 2.0 of the 
experimental data. This study presents the first permeability-limited PBTK model that explicitly 
considers PFOA-protein interaction for rats. Given all parameters used were obtained from in vitro 
assays rather than in vivo data fitting, our model provides an effective framework to test in vitro-
in vivo extrapolation and holds great promise for predicted toxicokinetics of per- and 
polyfluorinated alkyl substances in humans. 
2.1 Introduction 
Perfluorooctanoic acid (C7F15COOH, PFOA) is one of the most well-studied per- and 
polyfluoroalkyl substances (PFAS) that was widely used in industrial and consumer products.48 
The strong carbon-fluorine bonds in PFOA make it very resistant to metabolic and environmental 
degradation, which, coupled with its widespread use, results in its worldwide presence.3, 10, 49 
Although production of PFOA has been eliminated by many manufacturers,24 worldwide human 
exposure to PFOA is still continuing.50-53 
PFOA toxicokinetics have been studied extensively in mammals, and the results show that 
the substance is well absorbed orally and not metabolized.54-56 It is primarily accumulated in 
plasma, liver, and kidney, with lowest levels distributed to adipose and muscle.54, 57-61 In addition, 
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PFOA can be eliminated through urine and feces, with urine being the major route. It has been 
reported that renal elimination rates are species- and sex-dependent.62 For example, the half-life 
of PFOA in human blood was estimated to be about 3.5 years and no significant gender difference 
was observed.63 However, the clearance of PFOA in rats is considerably sex-dependent, with 
reported half-lives of several days and hours for male and female rats, respectively.64, 65 
Two principal underlying molecular mechanisms have been identified for PFOA 
toxicokinetics: protein binding and cell membrane transport. Studies revealed that PFOA is 
strongly bound to serum albumin as well as cytosolic fatty acid binding proteins (FABPs), which 
are pervasive in different tissues such as liver and kidney.37, 39, 66, 67 Therefore, binding to different 
proteins could be an important determinant for high accumulation in blood, liver, and kidney. For 
membrane transport, both passive diffusion and active transport facilitated by transporter proteins 
play important roles in cellular uptake of PFOA.40-42, 68 A number of transporters, such as organic 
anion transporters (Oats) and organic anion transporting polypeptides (Oatps) have been identified 
that are responsible for renal tubular excretion and reabsorption of PFOA in humans and rats.41, 42, 
68 
Due to its persistence and bioaccumulation, the potential human health risks of PFOA have 
received intense attention from environmental scientists and regulatory agencies.24 Especially, a 
number of physiologically based toxicokinetic (PBTK) modeling tools have been developed to 
inform risk assessment for PFOA in different species such as humans, rats and monkeys.30-36 All 
those models assume the chemical uptake rate to each tissue is mainly determined by blood flow 
rate rather than cell membrane permeability. By neglecting membrane permeability and its 
associated parameters, the flow-limited assumption simplifies the PBTK model process 
significantly. However, for chemicals with large molecular weights and/or ionic charges (e.g., 
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PFOA which has a molecular weight of 414.09 Da and is negatively charged at environmentally 
and physiologically relevant pH12), cell membrane permeability becomes the rate-limiting process 
for uptake and needs to be included in the PBTK model.29  
Based on the above considerations, we developed a permeability-limited PBTK model that 
explicitly considers cellular membrane permeability of PFOA through different tissues as well as 
the molecular mechanisms for PFOA toxicokinetics (i.e., protein binding and active transport 
process). We applied the permeability-limited PBTK model to estimate the plasma toxicokinetics 
and patterns of tissue distribution of PFOA in male rats, for which most protein-related parameters 
were available.  
Finally, one potential limitation of this PBTK model is that some mechanism-related 
parameters are either based on a single study (e.g., the equilibrium association constant of albumin 
for the rat) or extrapolated from in vitro studies (e.g., active transport rates in the kidney). The 
limited knowledge about those key parameters leads to a substantial amount of uncertainty in the 
PBTK model. To address this issue, hierarchical Bayesian analysis with Markov chain Monte 
Carlo (MCMC) was applied to reduce the uncertainty of parameters and improve the robustness 
of the PBTK model.69 With the optimized posterior parameters, the improved PBTK model was 
evaluated by comparing its prediction with both the prior model results and the experimental data 
from three separate studies,54, 58, 59 where different PFOA dose levels and administration routes 
were used (providing a total of even data sets) for male rats. 
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2.2 Materials and Methods 
2.2.1 Rat Model Structure 
As indicated in Figure 3, the model includes seven tissues: blood, kidney, liver, gut, 
muscle, adipose and the rest of the body. Since this is a permeability-limited model, the 
consideration of tissue subcompartments is required. Except for blood, each tissue contains both a 
vascular space and tissue space, the latter of which can be further divided into two 
subcompartments: interstitial fluid and tissue. To characterize absorption and elimination 
processes of PFOA, gut lumen, filtrate and bile compartments were incorporated in our model. 
The blood compartment functions as systemic circulation connecting each tissue 
compartment. In blood, PFOA binds to serum albumin based on the equilibrium association 
constant, K
 
a. Interstitial fluids of other compartments also contain albumin to which PFOA could 
bind.70, 71  
Enterohepatic circulation may play a role in the distribution of PFOA in liver72 and thus 
was considered in our model. Due to scarcity of data, we only included two transporters that could 
be associated with the cycling of PFOA in liver: Oatp1a1 and Ntcp, both of which are located at 
the basolateral membrane of hepatocytes.73 Oatp1a1 has been demonstrated to be able to transport 
PFOA,68 while for Ntcp, only the interactions with perfluorooctane sulfonate (PFOS) were 
reported.74 Given the structural similarity between PFOA and PFOS, we assume that Ntcp could 
also transport PFOA. Once in the hepatocyte, PFOA can bind to liver-type fatty acid binding 
protein (LFABP) in hepatocytes while the free fraction is available for excretion into the bile duct 
via passive diffusion. Biliary PFOA is then circulated to gut lumen, where reabsorption of PFOA 
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from the intestine back to systemic circulation can occur, as well as elimination of PFOA through 
defecation.  
The kidney is another major elimination tissue, involving glomerular filtration, renal 
clearance, renal reabsorption, and renal efflux processes. The free fraction of PFOA can transport 
from blood into filtrate through both glomerular filtration and renal clearance. The latter process 
is mainly mediated via organic anion transporters (Oat1 and Oat3) located at the basolateral 
membrane of proximal tubular cells.62 In filtrate, PFOA is actively reabsorbed by Oatp1a1 back to 
the tissue compartment (i.e., renal reabsorption),62 where PFOA can bind to two different proteins, 
L-FABP and α2μ-globulin (traditionally but erroneously called kidney fatty acid binding 
protein75), both of which are present in rat kidney tissue.76, 77 The free fraction of PFOA in kidney 
tissue might be excreted into blood through organic solute transporters (Ostα/β) (i.e., renal efflux). 
Based on the observation of lower kidney:blood PFOA concentration in male rats compared to 
female rats, it is hypothesized that male rats have more effective efflux transporters on the renal 
basolateral membrane excreting intracellular PFOA back to blood;42 Ostα/β and Mrp6 are 
proposed to be promising candidates for PFOA efflux.62 Given available kinetics data for Ostα/β, 
it was included in our model. 
Finally, muscle and adipose were selected for comparison to other tissues, since they 
typically have the lowest levels of PFOA.54, 59 All the remaining tissues were lumped into a single 
compartment, rest of body.  
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Figure 3. Rat model structure. 
There are seven tissues including blood (B), liver (L), gut (G), kidney (K), muscle (M), adipose (A), and “rest 
of body” (R). All tissues except blood contain a vascular space (e.g. KB for kidney), interstitial fluid (e.g. KF 
for kidney) and tissue space (e.g. KT for kidney). Blood flow rate for each tissue is indicated (e.g. QBK is the 
blood flow rate to kidney).  
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2.2.2 Model Parameterization 
All parameters used in our model were rat-specific, except capillary surface area, albumin 
concentrations in interstitial fluid compartments, and the transport kinetics of Ostα/β. The first two 
parameters were estimated from other mammalian studies,70, 71, 78 and Ostα/β kinetics was based 
on an uptake study in human cells.74 All these parameters are explained in detail below. 
2.2.2.1 Rat Physiology 
Physiological parameters were obtained from the literature. The average body weight of 
rats in each experimental dataset (Section 2.2.5) was used for model simulation. Fractional tissue 
volume, blood flow rate, interstitial fluid and blood volumes, and capillary surface areas for each 
compartment are summarized in Appendix Table 1. Other parameters including volume of bile, 
renal filtrate, and gut content as well as urinary, biliary, and fecal flow rates are also indicated. 
Detailed information on derivation of physiological parameters is provided in Appendix Table 1. 
2.2.2.2 Protein Binding 
In terms of the protein binding of PFOA, a total of three proteins were considered including 
albumin (in blood and interstitial compartments),39 liver-type fatty acid binding protein, LFABP 
(in both liver and kidney tissue compartment),37 and α2μ-globulin (only in the kidney tissue 
compartment);75 those proteins have all been demonstrated as important determinants for PFAS 
accumulation in blood, liver, and kidney. The linear model parameterized by free fraction of PFOA 
was used to model the protein binding process.79 As shown in equation 1, the free fraction of PFOA 
(ff), i.e., the ratio of free PFOA concentration (Cfree) to the total PFOA concentration in tissue 
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(Ctotal), is determined by the equilibrium association constant (Ka) and the maximum binding 








  (2-1) 
 
Here, ff is considered to be independent of Cfree and the protein binding for PFOA is therefore 
characterized by a constant parameter predefined by Ka and Bm. The Ka of albumin, LFABP and 
α2μ-globulin as well as the concentration of those proteins in different tissues (i.e., Bm) were 
obtained from the literature and shown in Appendix Table 2 and 3. 
2.2.2.3 Membrane Transport 
Both passive diffusion and active transport facilitated by proteins play essential roles in 
membrane transport of PFOA.80-84 To derive the mass balance equations for those processes, 
passive diffusion rates for each tissue and active transport rates for each relevant membrane 
transporter are required. For passive diffusion, the effective permeability (Peff) for each tissue was 
used to calculate the passive diffusion rate. As shown in equation 2, permeability is estimated 







Where J, the initial passive diffusion flux, was empirically determined by extracting in vitro data 
from Weaver et al.;80 the average value of J is around 0.13 nmol/mg protein/min and is converted 
to mol/s by scaling to the protein content of each tissue-specific cell type (Appendix Table 2). A 
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is the cellular surface area, which is assumed to be 4000 µm2 for a single cell.82 ∆𝐶  is the 
concentration of PFOA in the exposure medium (i.e., 10 µmol/L in the Weaver et al. study).80 
Once Peff is determined, the passive diffusion rate (k) between connected tissue 
compartments can be calculated as follows. 
For diffusion between blood (B) and the interstitial fluid compartment in each tissue (iF): 
 










𝑖  is the blood flow to each tissue, and 𝐴𝐵−𝑖𝐹 is the surface area of exchange between 
blood and fluid compartment (Appendix Table 1). 
For diffusion between the fluid (iF) and tissue (iT) subcompartment in each tissue, only 
permeability accounts for the overall mass transfer: 
 
 𝑘𝑖𝐹−𝑖𝑇 = 𝑘𝑖𝑇−𝑖𝐹 =  𝑃𝑒𝑓𝑓
𝑖 𝐴𝑖𝐹−𝑖𝑇 (2-4) 
 
For tissues containing filtrate, bile, or gut lumen, the diffusion between tissues and those 
subcompartments (iS) are: 
 
 𝑘𝑖𝑆−𝑖𝑇 =  𝑃𝑒𝑓𝑓
𝑖 𝐴𝑖𝑆−𝑖𝑇 (2-5) 







𝐶−𝑊 is the steady-state cell-water concentration ratio, which can be extrapolated from 
in vitro data.82 The values of 𝐶𝑅𝑠𝑠
𝐶−𝑊 for liver to bile, kidney to filtrate, and enterocyte to gut lumen 
are shown in Appendix Table 4. 
Regarding active transport, a total of five transporters are responsible for four active 
transport processes: (i) renal clearance, which involves Oat1 and Oat3 located at the basolateral 
membrane of proximal tubular cells; (ii) renal reabsorption, which involves Oatp1a1 located at the 
apical membrane of proximal tubular cells; (iii) renal efflux, which relates to Ostα/β located at the 
basolateral membrane of proximal tubular cells; and (iv) hepatocyte absorption, which relates to 
Oatp1a1 and Ntcp located at the basolateral membrane of hepatocytes.62 Similar to the passive 
diffusion process, Fick’s Law was used to derive the coefficients for those four active transport 
processes; the only difference is that the J parameter in equation 2 corresponds to the flux of 
transporter-expressing cell rather than the passive diffusion flux. The J value for each transporter 
and the calculated active transport coefficients are shown in Appendix Table 5. Finally, the active 
transport rate for each process can be derived by multiplying the transport coefficient by the 
surface area for exchange of the corresponding tissue. 
2.2.3 Mass Balance Equations 
Our PBTK model is based on permeability-limited equations that consider three or four 
subcompartments for each tissue. Each compartment is described by mass balance equations based 
on protein binding of PFOA and the transport between connected compartments. 
For an individual tissue i (i = A, G, K, L, M, and R, for adipose, gut, kidney, liver, muscle, 
and rest of body, respectively), the mass of free PFOA in each subcompartment j (j = F and T, for 
fluid and tissue subcompartment, respectively) can be determined by: Mfree = M ×  𝑓𝑓, where ff 
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is the free fraction parameter of PFOA. The value of ff for subcompartment ij (i.e., 𝑓𝑓 𝑖𝑗) is 



























 is the concentration of protein p (i.e., albumin, L-FABP or α2μ-globulin) in 
subcompartment ij. 𝐾𝑎
𝑝
 represents the association constant of protein p. 
Using the free fraction parameter to calculate Mfree in each compartment, the mass balances 
can then be expressed as detailed in equations 11-19 below. 
In the blood compartment (B), which is in contact with and can be considered as a 







iF  − ∑ bB−iFMfree
B  + bFiltrate−BMfree
Filtrate − bB−FiltrateMfree
B
ii  (2-11) 
 














iF  (2-12) 
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iT  (2-13) 
 
For tissues (i = K, L, and G) that contain the additional compartments of filtrate, bile, or gut lumen 
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free represents free PFOA in ij subcompartment, which can freely transport between 
compartments. Parameters bij-im and b
ij-jm 
active are first-order rate constants for passive diffusion and 
active transport between subcompartments ij and im (j ≠ m), respectively. Those rate constants are 
determined by the transport rate parameters divided by the volume of the corresponding 
compartment. For example, 𝑏𝑖𝐹−𝑖𝑇 =
𝑘𝑖𝐹−𝑖𝑇
𝑉𝑖𝐹
, where k is the passive diffusion rate from iF to iT 




Figure 4. Workflow of hierarchical Bayesian framework for the permeability-limited PBTK model. 
The PBTK model is a function of chemical-related parameters (𝜽𝒊), physiological covariables (𝝍𝒊), exposure 
scenarios (𝑬𝒊) and sampling time points (𝒕𝒊). The individual parameters for each subject i (𝜽𝒊) are drawn from 
the population distribution with mean (𝝁) and variance (𝚺). The experimental error term (𝜺) has a normal 
distribution with mean 0 and variance (𝝈𝟐). Based on the prior information of 𝝁, 𝚺 and 𝝈𝟐 and experimental 
data points (𝒀𝒊), the hierarchical Bayesian framework with MCMC simulation was used to generate the 
posterior distribution for those parameters. 
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2.2.4 Hierarchical Bayesian Framework 
The hierarchical Bayesian approach85 was employed to reduce the uncertainty and 
variability of the permeability-limited PBTK model for PFOA in the male rat. The Bayes Rule is 
shown in the following equation:85  
 
 𝑃(𝜃|𝑌) =  
𝑃(𝜃)𝑃(𝑌|𝜃)
∫ 𝑃(𝜃)𝑃(𝑌|𝜃)𝑑𝜃
  (2-20) 
 
Where θ is the PBTK model parameter vector to be estimated. Y is the measured toxicokinetic 
data for PFOA. P(θ|Y) is the posterior distribution of the model parameters, and P(θ) is the prior 
distribution that describes the prior knowledge of parameters. P(Y|θ) is the likelihood of the 
experimental dataset. In order to perform Bayesian inference, first of all, prior distributions of 
model parameters need to be defined. Here, we mainly focus on the key parameters that are related 
to PFOA toxicokinetics mechanism due to the high uncertainty and sensitivity of those parameters. 
The prior distributions for those parameters were assumed based on the literature (e.g., most of 
biological parameters were assumed to be log-normal distributions). Next, the likelihood of the 
observed data set can be calculated based on the PBTK model. Given the likelihood and prior 
distribution of the parameter, the posterior distribution for those parameters can be inferred from 
the Bayes Rule. However, it is almost impossible to obtain an analytical expression for P(θ|Y). For 
this reason, the MCMC technique will be employed to estimate the posterior distribution for the 
parameters. MCMC is a powerful computational tool to provide samples of parameters without 
the analytical results of P(θ|Y).85  
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As indicated in Figure 4, the hierarchical structure consists of two major parts: the subject 
level and the population level. At the subject level, for each individual i, the PBTK model (i.e., 
function f) was used to predict the PFOA concentration-time profiles based on given parameters 
including chemical-related parameters (𝜃𝑖), physiological covariables (𝜓𝑖), exposure scenarios 
(𝐸𝑖 ) and sampling time points ( 𝑡𝑖 ). The prediction results are related to the experimentally 
measured concentration data (𝑌𝑖) through the following error model: 
 
 𝑙𝑜𝑔𝑌𝑖 = 𝑙𝑜𝑔𝑃 +  𝜀 (2-21) 
 
Where the error term 𝜀 is a normal variable with mean set equal to 0 and variance to 𝜎2. At the 
population level, to reflect the interindividual variability, chemical-related parameters (𝜃𝑖) were 
considered to be generated from a multivariate population distribution, with population mean (𝜇) 
and variance (Σ). The prior distribution of the 𝜇 and Σ for each parameter is discussed in Section 
2.2.4.1. With the prior knowledge of the model parameters and the above hierarchical Bayesian 
framework, the Markov chain Monte Carlo (MCMC) technique was employed to numerically 
estimate the posterior distribution for the model parameters. Finally, the resulting change in the 
central estimate and the uncertainty and variability of those parameters were analyzed. 
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Table 1. Summary of the parameters of the PBTK model selected for MCMC analysis. 
Parameters Symbol Values Unit 
Confidence 
Factor (Cf) 
Effective permeability of blood PeffB 0.179 mm/h 5 
Effective permeability of kidney PeffK 0.158 mm/h 5 
Effective permeability of liver PeffL 0.185 mm/h 5 
Steady-state cell-water concentration 
ratio of kidney 
CRssK 6.19 unitless 5 
Steady-state cell-water concentration 
ratio of liver 
CRssL 7.28 unitless 5 
Renal clearance rate constant Pbclear 0.994 mm/h 5 
Renal reabsorption rate constant Pbreab 0.425 mm/h 5 
Renal efflux rate constant Pbefflux 0.497 mm/h 5 
Absorption rate constant of hepatocyte Pbabs 0.641 mm/h 5 
Association constant of albumin Ka
Alb 2.418×104 M-1 5 
Association constant of LFABP Ka
LFABP 1.35×105 M-1 5 
Note: for the association constants, the values represent measured association constants multiplied by the 
number of binding sites.  
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2.2.4.1 Prior Distributions 
As described above, many parameters are involved in the PBTK model (68 in all). To 
reduce the computational cost for the MCMC simulation, only the chemical-related parameters to 
which the model was previously shown to be most sensitive were selected for uncertainty analysis. 
Based on the sensitivity analysis results (Appendix Table 6), these parameters include the 
equilibrium association constants, Ka, between PFOA and albumin and LFABP, Peff of blood, liver 
and kidney,  𝐶𝑅𝑠𝑠
𝐶−𝑊 of liver and kidney, and active transport rates of the four active transport 
processes discussed above (Table 1). Other parameters, such as physiological parameters, Ka of 
α2μ-globulin, and Peff of gut, muscle and adipose, were considered as fixed values in the 
hierarchical Bayesian framework since those parameters were well-studied (low uncertainty) or 
much has much less influence on the model performance (Appendix Table 6). 
Next, as described in Figure 4, the population mean (µ) of each selected parameter was 
assigned with a log-normal prior distribution with hyperparameter mean (M) and standard 
deviation (S). The M value for each parameter was derived from the literature, as shown in Table 
1; the S value was calculated based on equation:  𝑆 =  𝑒ln (√𝐶𝑓), where Cf represents confidence 
factor, which is an intuitive measure of variance in log-normal distributions.86 For example, a Cf 
of 2 indicates that 95% of the values lie between ½ and 2 times the median. Given the scarcity of 
the available data for those parameters, a value of 5 was assigned for them indicating the high 
uncertainty of their prior distributions (Table 1). 
The prior distributions for the population variance of those parameters (Σ2) were assumed 
to be inverse gamma distribution: Σ2 ~ 𝐼𝑛𝑣𝐺𝑎𝑚𝑚𝑎(𝛼, 𝛽), where the shape parameter 𝛼 is set to 
3, and the scale parameter 𝛽 is set to 0.5 based on previous studies.69, 87 The quantities M, S, 𝛼 and 
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𝛽 are hyperparameters that embody prior knowledge of the uncertainty and variability of the model 
parameters. 
Finally, considering the high uncertainty and variation of experimental data among 
different studies (e.g., 1 mg PFOA/kg BW IV and oral dose scenarios from the Kemper54 and the 
Kim et al.58 study), the prior distribution of the experimental error term (𝜎2) was modeled as a 
noninformative uniform distribution with a lower bound of 0.01 and upper bound of 3.3 for all 
experimental measurements.69, 87 
2.2.4.2 MCMC Simulation 
With the prior information of the population mean (µ) and variance (Σ2) and experimental 
error term (𝜎2), the joint posterior distribution given the experimental data (Y) can be determined 
based on Bayes’ theorem, as shown in equation 22.85 
 
 𝑝(𝜃, 𝜇, Σ2, σ2 | 𝑌) ∝ 𝑝(𝑌 | 𝜃, σ2) × 𝑝(𝜃 | 𝜇, Σ2) × 𝑝(𝜇) × 𝑝(Σ2) × 𝑝(𝜎2) (2-22) 
 
𝑝(𝜇) , 𝑝(Σ2)  and 𝑝(𝜎2)  are the probability calculated from corresponding prior distributions. 
𝑝(𝜃 | 𝜇, Σ2) is the probability of individual chemical-related parameter 𝜃, which is assumed to be 
log-normally distributed as 𝑙𝑜𝑔(𝜃) ~ 𝑁(log(𝜇) , Σ2). Finally, 𝑝(𝑌 | 𝜃, σ2) is the likelihood of the 
experimental data Y, which is determined based on 𝑙𝑜𝑔(𝑌) ~ 𝑁(log(𝑃) , σ2), where P is the 
predicted concentration-time data from the PBTK model given a set of parameters (i.e., 𝑃 =
𝑓(𝜃, 𝜓, 𝐸, 𝑡), as in Figure 4). 
Due to the nonlinearity of the PBTK model, it is impossible to acquire an analytical 
expression for 𝑝(𝜃, 𝜇, Σ2, σ2 | 𝑌). Instead, the Delayed Rejection Adaptive Metropolis (DRAM) 
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algorithm,88 a commonly used MCMC sampling technique, was employed to numerically 
approximate the joint posterior distribution. DRAM was selected because it is highly efficient and 
has been successfully applied in toxicokinetic models.69 Here, a total of four Markov chains were 
constructed in the simulation. For each chain, the total number of iterations was set to 300000, 
with the first 150000 iterations as a “burn-in” period and the last 50000 iterations as the output 
samples for posterior distribution analysis. 
2.2.4.3 Posterior Analysis and Evaluation 
After an MCMC simulation, the convergence of the posterior distributions needs to be 
verified before further analysis. The Gelman-Rubin diagnostic was used to assess the samples 
generated from the MCMC method.89 Specifically, the potential scale reduction factor (?̂?) was 
calculated for each parameter distribution. When the posterior distribution becomes stationary, ?̂? 
is close to 1. An ?̂? value of 1.2 or less is considered to be converged for the distribution, as 
recommended by Gelman et al.90 
Based on the MCMC output, the posterior quantiles and density plots for the distribution 
of each selected model parameter were generated for analysis. The PBTK model was then run with 
the updated parameter distributions and its output was compared with the model results generated 
with prior parameter distributions. Finally, based on the new predicted concentration-time data, 
toxicokinetic parameters including half-life, clearance, the maximum PFOA concentration in 
plasma (Cmax), and the time required to reach the peak concentration (Tmax) were calculated and 
compared with experimental data from other studies. 
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2.2.5 Experimental Data 
Several studies on toxicokinetics and tissue distribution of PFOA in male rats were reported 
for both oral and IV dosing.54, 58, 59 In order to compare different administration routes, data on 
single oral and IV doses of 1 mg PFOA/kg body weight (BW) were chosen for our model 
evaluation.54, 58 Moreover, data from a single oral dose of 0.1 mg PFOA/kg BW and IV dose of 
0.041 mg PFOA/kg BW were incorporated to verify model performance at low doses.54, 59 This is 
of particular toxicological relevance since people in Europe and North America are exposed to low 
levels of PFOA, with estimated daily intakes in the range of 1 to 130 ng PFOA/kg BW.91 A total 
of seven experimental datasets collected from three different studies were used and are briefly 
described below. 
 





Sampling Time for Tissues Rat Strain References 
oral 1 mg/kg Sample from blood at 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 
48, 72, 96, 120, 144, 168, 192, 240, 288, 336, 384, 432, 




oral 0.1 mg/kg 
IV 1 mg/kg 
oral 1 mg/kg 
Sample from liver, kidney, gut, muscle and adipose after 
672 hours 
oral 1 mg/kg Sample from blood at 6, 12, 24, 48, 96, 144, 192, 240, 
288 hours; Sample from liver and kidney after 288 hours 
Sprague-
Dawley 
Kim et al.58 
IV 1 mg/kg 
IV 0.041 mg/kg 
Sample from blood at 5, 15, 45, 90, 120, 150, 210, 270, 
300 minutes; Sample from liver and kidney after 120 
minutes 
Wistar Kudo et al.59 
*All experiments used single doses. 
 
As summarized in Table 2, we extracted four datasets from the Kemper study,54 in which 
toxicokinetics and distribution of PFOA at different dose levels were investigated for both male 
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and female rats. The first two datasets are the toxicokinetic data for male rats administered by two 
routes: oral and IV dose. Specifically, four male Sprague-Dawley (SD) rats were dosed 1 mg 
PFOA/kg BW through oral or IV administration, respectively, then blood samples were collected 
at different times and analyzed. In addition, a third experiment measuring terminal tissue 
distribution was chosen from the same study for comparison to predicted PFOA levels in each 
organ. In this experiment, 1 mg 14C-FPOA/kg BW oral dose was administered to four male SD 
rats. After 28 days, tissue samples were collected for analysis. Finally, the fourth dataset is the 
toxicokinetic experiment with a dose level of 0.1 mg PFOA/kg BW, where four male SD rats were 
orally dosed, and the PFOA concentration in blood collected at different times were analyzed.  
In the second study conducted by Kim et al.,58 two datasets, corresponding to IV and oral 
administration routes, respectively were extracted. Briefly, 1 mg PFOA/kg BW oral and IV dose 
were administrated to 5 male and 5 female SD rats. Blood samples were collected and analyzed at 
different time points. At the end tissue samples including liver, kidney, heart, lung, and spleen 
were collected for analysis. 
To further assess our model, we selected another dataset from a third study59 where four 
male Wistar rats were intravenously dosed with the low dose of 0.041 mg [1-14C]PFOA/kg BW. 
PFOA concentration in blood collected at different time points and tissues, including liver, kidney, 
intestine, testis, spleen, fat, heart, lung, brain, stomach, and carcass, all analyzed after 2 hours, 
were available. 
For all three studies (seven datasets), data were directly taken from tables, where available, 
or extracted from plots by WebPlotDigitizer tool (https://automeris.io/WebPlotDigitizer/). 
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2.2.6 Software 
The PBTK model and MCMC simulation were programmed in R (https://www.r-
project.org/) using mrgsolve (https://mrgsolve.github.io/), a package designed for solving ordinary 
differential equations, for PBTK model development. The MCMC simulation was coded using the 
FME package, which provides convenient functions for the DRAM algorithm.92 
2.3 Results 
2.3.1 Convergence Diagnosis 
The trace plots for Markov chains in MCMC are shown in Appendix Figure 1-3. As 
indicated, no visible trends or changes were observed in the trace plot for each model parameter, 
suggesting good convergence of the distribution for each parameter. In addition, Gelman-Rubin 
diagnostic results (Appendix Table 7) show that all parameters have potential scale reduction 
factor (PSRF) values between 1.001 and 1.02, with upper confidence limits between 1.002 and 
1.056. The multivariate PSRF value, which forms the upper bound of PSRF for any linear 
combination of the parameters, is 1.09. All PSRF values are less than 1.2, indicating the posterior 
distributions in MCMC have reached equilibrium and can be used for further analysis. 
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2.3.2 Posterior Distribution Analysis 
Table 3. Percentiles of the prior and posterior distribution for each parameter. 
Parameters 
Prior Distribution Posterior Distribution 
2.50% 50% 97.50% 2.50% 50% 97.50% 
PeffB 0.037 0.179 0.868 0.560 0.791 0.865 
PeffK 0.033 0.158 0.764 0.038 0.186 0.672 
PeffL 0.038 0.185 0.898 0.042 0.192 0.827 
CRssL 1.504 7.280 35.246 1.634 7.720 32.756 
CRssK 1.279 6.190 29.969 1.521 6.776 26.044 
Pbclear 0.205 0.994 4.810 0.304 1.705 4.563 
Pbreab 0.088 0.425 2.057 0.094 0.228 1.423 
Pbabs 0.132 0.641 3.102 0.138 0.337 2.273 
Pbefflux 0.103 0.497 2.405 0.108 0.267 1.233 
Ka
Alb 4.994×103 2.418×104 1.171 ×105 2.28×104 3.582×104 5.686×104 
Ka
𝐿𝐹𝐴𝐵𝑃 2.788×104 1.35×105 6.536×105 3.289×104 1.439×105 4.769×105 
 
 
The percentiles (2.5%, 50% and 97.5%) and density plot comparisons between prior and 
posterior distribution for each model parameter are shown in Table 3 and Figure 5, respectively. 
After updating with experimental data, the posterior distributions of the population mean for all 
parameters were substantially narrower than their prior distributions, indicating that the 
uncertainties of those parameters were substantially reduced. In addition, an obvious shift was 
observed in the density plot for some parameters (e.g., PeffB and Ka
Alb in Figure 5). The percentiles 
of distributions also showed significant changes (defined by larger than ± 20% of prior values93) 
between prior and posterior for some parameters. Specifically, the posterior median of the effective 
permeability of blood (PeffB) was 4.4 times higher than its prior median. In addition, the posterior 
median of the Ka
Alb value (i.e., the association constant of albumin multiplied by the number of 
binding sites) is 3.582×104 M-1, which is increased by 48% compared to its prior median. Finally, 
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the posterior medians of all the active transport parameters were substantially different from their 
prior values: after updating with experimental data, the renal clearance rate constant (Pbclear) 
increased by 71.5%, the absorption rate constant of hepatocyte (Pbabs), renal reabsorption rate 




Figure 5. Density plots of the prior and posterior distribution for each parameter. 
2.3.3 Model Evaluation 
With the generated posterior parameter distributions, the PBTK model was used to simulate 
the plasma toxicokinetics and tissue distribution of PFOA in male rats and the model was evaluated 




Figure 6. PFOA toxicokinetics in plasma under different dose scenarios. 
The grey line represents model results using prior parameter distributions; the black line is with the posterior 
distributions. The upper, middle, and lower lines indicate the 97.5th, 50th, and 2.5th percentiles of the 
predicted results, respectively. Red triangles, green squares, and blue circles represent the data sets extracted 
from the works of Kemper 2003, Kim et al. 2016, and Kudo et al. 2007, respectively. The first 5 hours time-
course behavior for oral dose was zoomed to show its up trend at the beginning phase.  
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2.3.3.1 Plasma toxicokinetics 
As shown in Figure 6, all experimental data sets fall within the 95% range of the prior 
model predictions. Both prior and posterior model predictions indicated similar time-course 
behavior to the experimental data. However, the 95% range of the posterior prediction (black line) 
was substantially smaller than that of the prior prediction (grey line), demonstrating a significant 
decrease in the model uncertainty. In addition, most experimental data fall within the 95% range 
of the posterior prediction of PFOA concentration in plasma, except for data from the Kim et al 
study,58 which show a higher elimination rate. It is worth noting that even under the same dose 
scenarios (e.g., 1 mg PFOA/ kg BW IV and oral dose), the PFOA concentration profiles are quite 
different between Kim et al58 and the Kemper study54, illustrating the significant variation that can 
be found among different experimental studies for PFOA toxicokinetics. 
Finally, based on the predicted PFOA concentration profiles in plasma, different 
toxicokinetic parameters were estimated and compared with the experimental results from the 
Kemper study.54 As shown in Table 4, in comparison with experimental data, the posterior model 
results demonstrate much improvement from the prior model for the half-life, clearance of PFOA, 
and maximum plasma concentration of PFOA (Cmax); the posterior predicted values for those 
toxicokinetic parameters fall well within a factor of 1.5 of the experimental data for three different 
dose scenarios. The half-life seems to be independent of dose scenarios and is calculated as 7.90 
days, which is in very good agreement with the half-life values from other experimental studies 
(range from 5.63 to 15 days).56, 94-96 The posterior clearance of PFOA is also very similar under 
different dose cases and has an average value of 25.70 mL/day/kg, which falls within the range of 
other experimental data (from 21.5 to 50.5 mL/day/kg).94, 95, 97 For the parameter of the time 
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required to reach the maximum concentration (Tmax), the prior and posterior model predictions are 
underestimated by a factor of around 2 and 3.5, respectively. 
 
Table 4. Comparison of toxicokinetic parameters between model prediction and experimental data. 
Dose Scenario Half-life (day) 
Clearance 
(mL/day/kg) 
Cmax (ng/g) Tmax (h) 
0.1 mg/kg oral 
Prior 14.739 ± 15.547 69.310 ± 71.964 424.651 ± 147.354 5.154 ± 3.319 
Posterior 7.900 ± 0.662 26.948 ± 1.715 546.219 ± 50.851 2.874 ± 0.261 
Experiment 8.41 ± 1.56 23.10 ± 5.76 598 ± 127 10.25 ± 6.45 
1 mg/kg oral 
Prior 15.223 ± 19.857 65.829 ± 71.657 4245.631 ± 1463.333 5.095 ± 3.111 
Posterior 7.912 ± 0.673 25.175 ± 1.545 5479.220 ± 531.690 2.885 ± 0.272 
Experiment 5.76 ± 1.33 20.9 ± 3.79 8431 ± 1161 9.00 ± 3.83 
1 mg/kg IV 
Prior 15.410 ± 17.516 68.775 ± 91.513 - - 
Posterior 7.894 ± 0.668 24.990 ± 1.553 - - 





Figure 7. PFOA terminal tissue distribution under different dose scenarios. 
(a) 28 days after 1 mg PFOA/kg BW oral dose; (b) 12 days after 1 mg PFOA/kg BW IV dose; (c) 12 days after 
1 mg PFOA/kg BW oral dose; (d) 2 h after 0.041 mg PFOA/kg BW IV dose. The grey and black lines 
represent the 95% range of the model predictions using prior and posterior parameter distributions, 
respectively. Color bars are experimental data sets from different studies (a: Kemper 2003, b and c: Kim et 
al. 2016, and d: Kudo et al. 2007) All experimental data are shown as mean ± standard deviation. 
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2.3.3.2 Tissue Distribution 
Figure 7 shows the comparison of PFOA tissue distribution between model predictions 
(with both prior and posterior parameter distributions) and experimental results under different 
dose scenarios. As indicated in Figure 7, our model was able to successfully predict the tissue 
distribution patterns for PFOA in long-term simulations (i.e., after 12 or 28 days): liver > kidney 
> gut > muscle ≈ adipose. For a short-term dosing scenario (e.g., 2 hours), the predicted PFOA 
concentration in liver was significantly lower than the measured data. Similar to the plasma 
toxicokinetics results, the uncertainty for posterior model predictions was reduced substantially 
compared with the prior model. Most measured PFOA concentrations in each tissue fall well 
within or overlap with the 95% prediction range, except for the data from the Kudo et al. study.59  
A further comparison was performed between the mean of experimental data in different 
tissues and the mean of the model predictions. Both prior and posterior models are able to predict 
most of PFOA tissue distributions within a factor of 4 of the experimental data. However, the 
posterior model indicates better performance compared with prior model results. For long-term 
simulations, the posterior model predictions are well within a factor of 2 of measured 
concentrations for both oral and IV dose. For short-term dosing (i.e., the Kudo et al. study59), the 
hepatic PFOA concentration was underestimated by the PBTK model, but is within a factor of 2.6. 
2.4 Discussion 
In this study we developed a permeability-limited PBTK model that explicitly considers 
PFOA-protein interactions for toxicokinetics and distribution of PFOA in male rats. In addition, 
the hierarchical Bayesian framework with MCMC simulation was employed to reduce the 
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uncertainty of the model and improve its robustness. With the help of the Bayesian framework, 
not only were the uncertainties of the posterior parameters substantially reduced, but the PBTK 
model predictions also became more reliable and meaningful. For example, the toxicokinetic 
parameters such as half-life and clearance of PFOA estimated with posterior parameters are well 
within a factor of 1.5 of the experimental data, while the prior calculated toxicokinetic parameters 
fall within a factor of 1.8 to 3.2 of the experimental data. The good agreement between the 
simulation results and experimental data illustrates our model’s ability to predict the toxicokinetics 
and tissue distribution of PFOA in rats. Although the PBPK model with posterior parameters 
demonstrates better performance than the prior model, it is worth pointing out that this is because 
the posterior model used the experimental data to update the parameter distributions. In other 
words, the posterior model performance relies on the accuracy of the available experimental 
datasets. Given the substantial difference between the Kim et al58 and Kemper studies,54 if one of 
those studies turns out to be unreliable, it may be tuning the model in the wrong direction. On the 
other hand, the prior PBPK model, while it has high uncertainty, relies on no in vivo toxicokinetics 
data and thus could be less subject to bias. 
2.4.1 Molecular Mechanisms Driving PFOA Toxicokinetics 
With the Bayesian statistical framework, the PBTK model provides more insight into the 
molecular mechanisms that result in the observed PFOA toxicokinetics. As indicated in Table 3, 
the posterior median of the association constant for albumin ( Ka
Alb ) increased substantially 
compared to its prior value. It is worth pointing out that only one study was available for the prior 
knowledge of Ka
Alb in rats, and its association constant value (3.1×103 M-1 × 7.8 binding sites39) 
is much smaller compared with the Ka values in humans (e.g., 3.12×104 M-1 × 13 binding sites98 
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and 1.26×104 M-1 × 2.4 binding sites66) and bovines (e.g., 4.36×104 M-1 × 1 binding sites99). Both 
our model prediction and the comparison with other experimental data seem to indicate the current 
Ka
Alb value for rat is a little low and more studies are needed to measure Ka
Alb for PFOA with rat 
serum albumin. 
Another important insight is about the renal elimination of PFOA. From Table 4, compared 
with the prior half-life parameter (a mean of around 15 days), the posterior values (7.9 days) 
decreased substantially, indicating an increase in the renal elimination of PFOA. The major reason 
for this is due to the significant increase in the renal clearance rate constant (Pbclear) and the 
decrease in both the renal reabsorption rate (Pbreab) and efflux rate (Pbefflux), as shown in Table 
3. All those active transport processes were facilitated by different transporters. Although a total 
of five transporters were considered for the renal elimination process, other transporters such as 
Oatp4c1 and multidrug resistance-associated proteins (Mrps) located at the proximal tubular cells 
were not included due to limited information on their transport kinetics.62 However, our model 
results indicate that those transporters may have the potential to significantly affect the elimination 
of PFOA, and more in vitro data are needed to evaluate that possibility. 
Finally, our model performed very well for long-term dosing simulations, however, in the 
short-term dosing case (i.e., the 2-hour experiment from Kudo et al.59), the PFOA concentration in 
the liver was substantially underestimated by the model. This could be attributed to cellular 
membrane binding of PFOA at the beginning phase of distribution to the liver. In fact, Kudo et 
al.59 showed that 2 hours after dosing, around 97% of PFOA was found in the membrane fraction. 
Therefore, PFOA might bind to some membrane components (e.g., protein or phospholipids100), 
which slows down the distribution of PFOA to liver in a short period. In long-term simulation, it 
seems the membrane binding of PFOA has a negligible effect on the tissue distribution (Figure 7). 
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2.4.2 Model Limitations 
The first limitation on the Bayesian framework is that the prior knowledge is very limited 
for some model parameters, especially those related to protein binding and active transport 
processes. For example, the active efflux transporter Mrps, which is located at both the basolateral 
and apical membranes of proximal tubular cells, are dominant in female rats and could be 
responsible for the substantial gender difference in PFOA elimination between male and female 
rats.62 However, due to the lack of information on the transport kinetics of Mrps, a female rat 
model for PFOA was not considered in this study. In addition, the computational cost of MCMC 
simulations is very large, especially for a complex PBTK model. In this study, all the physiological 
parameters were fixed during MCMC simulation to reduce the computational burden, so the 
opportunity to refine all parameters in the model was missed. 
2.4.3 Call for Data 
More data are required to further improve the PBTK model and generalize it to other 
species and other PFAS. First, data are needed on more PFAS-protein interactions, such as the 
transporter Mrps, which has the potential to significantly affect PFAS elimination, but for which 
very limited information is currently available. Given the importance of the equilibrium 
association constant of albumin in the PBTK model, more accurate measurements are also 
necessary for model validation. PFAS-protein interaction data could be obtained through in vitro 
studies or estimated with molecular modeling tools (e.g., molecular docking and molecular 
dynamics). In addition, measurements of the membrane permeability for different tissues (e.g., 
blood vessels, liver, and kidney) are needed to validate the estimated posterior distributions for 
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those parameters (Table 3). Those measurements could be obtained using cell-based in vitro 
experiments, as demonstrated in the Weaver et al. study.80 Finally, more in vivo toxicokinetic data 
on PFAS are needed for Bayesian analysis of the PBTK model. As shown in Figure 3, even under 
the same dose scenarios, there is a huge difference between the toxicokinetics data from Kim et 
al.58 and Kemper54 (e.g., under the same 1 mg/kg oral dose scenario, after 12 days, the PFOA 
concentration in plasma of the Kemper study is 10 times higher than that of the Kim et al. study). 
More experimental data are needed to reduce the variability in observations, as well as to better 
understand actual inter-individual and intra-population variability. 
In conclusion, this Chapter focused on the PBTK model, which serve as the top level of 
the three-level hierarchical framework for PFAS risk assessment (Figure 2). Specifically, we 
developed a permeability-limited PBTK model that can be successfully used to predict the 
toxicokinetics and tissue distribution of PFOA in male rats. With the help of the hierarchical 
Bayesian framework, not only were the uncertainties of the posterior parameters substantially 
reduced, but the PBTK model predictions also became more robust: with the posterior parameters, 
most of the predicted plasma toxicokinetic parameters (e.g., half-life) and tissue distributions fell 
well within a factor of 2.0 of the experimental data. In addition, the PBTK model could provide 
insights into the molecular mechanisms that result in the observed PFOA toxicokinetics: PFAS-
protein binding, membrane permeability and active transport. As discussed above, the large 
difference in the optimized Ka
Alb shows that more especially species-specific data are needed for 
PFAS-protein binding, which is challenging given the large number of PFAS. Therefore, reliable 
methods are needed to predict these interactions, and Chapter 3.0 will try to address this persistent 
gap using molecular modeling. 
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3.0 Development of a Molecular Dynamics Workflow to Predict Relative Protein Affinity 
for Per- and Polyfluoroalkyl Substances (PFAS) 
This chapter is reproduced in part with permission from: 
Cheng, W. and Ng, C. A. Predicting relative protein affinity of novel per- and 
polyfluoroalkyl substances (PFASs) by an efficient molecular dynamics approach. Environmental 
Science & Technology 2018, 52 (14), 7972-7980. Copyright 2018 American Chemical Society. 
[https://pubs.acs.org/doi/abs/10.1021/acs.est.8b01268] 
This chapter is also reproduced in part based on: 
Cheng, W., Doering, J. A., LaLone, C. and Ng, C. A. Integrative Computational 
Approaches to Inform Relative Bioaccumulation Potential of Per-and Polyfluoroalkyl Substances 
Across Species. Toxicological Sciences, 2021, 180 (2), 212-223. By permission of Society of 
Toxicology. 
 
With the phasing out of long-chain per- and polyfluoroalkyl substances (PFAS), a wide 
variety of alternative PFAS have increased production to fill market demand. However, very little 
is known about the bioaccumulation potential of these replacement compounds. Here, we 
developed a modeling workflow that combines molecular docking and molecular dynamics 
simulation techniques to estimate the relative binding affinity of PFAS for liver-type fatty acid 
binding protein (LFABP). To demonstrate the power of the workflow, we first tested 15 legacy 
and replacement PFAS and two well-studied LFABPs (i.e., hLFABP and rLFABP for human and 
rat LFABP) to inform the bioaccumulation potential for novel PFAS. Moreover, we probed the 
bioaccumulation potential across different species by examining LFABP interactions across 7 
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different species (i.e., human, rat, chicken, zebrafish, rainbow trout, fathead minnow, and Japanese 
medaka) for 9 PFAS. The predicted results were evaluated by comparing with experimental data 
extracted from three different studies. There was good correlation between predicted free energies 
of binding and measured binding affinities, with correlation coefficients of 0.97, 0.79, and 0.96, 
respectively. With respect to replacement PFAS, our results suggest that EEA and ADONA are at 
least as strongly bound to rLFABP as perfluoroheptanoic acid (PFHpA), and to hLFABP as 
perfluorooctanoic acid (PFOA). For F-53 and F-53B, both have similar or stronger binding 
affinities than perfluorooctane sulfonate (PFOS). Given that interactions of PFAS with proteins 
(e.g., LFABPs) are important determinants of bioaccumulation potential in organisms, these 
alternatives could be as bioaccumulative as legacy PFAS, and are therefore not necessarily safer 
alternatives to long-chain PFAS. For bioaccumulation potential across species, Human, rat, 
chicken and rainbow trout had similar binding affinities to one another for each PFAS, whereas 
Japanese medaka and fathead minnow had significantly weaker LFABP binding affinity for some 
PFAS. This result indicates that human, rat, chicken, zebrafish or rainbow trout seem to be better 
representative species of the higher range of vertebrate bioaccumulation potential of PFAS than 
Japanese medaka and fathead minnow. 
3.1 Introduction 
Per- and polyfluoroalkyl substances (PFAS) are a diverse group of compounds that have 
been used in a broad range of industrial and consumer products (e.g., fire-fighting foams, food 
contact materials, and apparel).1-6 Due to their persistence, bioaccumulation and toxicity, the long-
chain PFAS have been phased out for the majority of uses.24, 25, 57 To take their place, 
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manufacturers have started using alternatives that include shorter-chain homologues of PFOA and 
PFOS, as well as perfluoroether carboxylic acids (PFECAs) and perfluoroether sulfonic acids 
(PFESAs).24, 25, 101, 102 A number of those fluorinated alternatives used in industrial and consumer 
products have been identified in a recent review paper by Wang et al.25 And these alternatives have 
also been widely detected in the environment and organisms.103-106 However, the identity and 
frequency of use of many other alternative PFAS remains largely unknown, leading scientists to 
employ extensive non-target analytical techniques to puzzle out the structures present in complex 
environmental mixtures of PFAS.26, 107-109 In addition, limited information is known on the 
potential impacts of alternative PFAS on humans and the environment; especially, there is a lack 
of information on the bioaccumulation potential and toxicity of PFECAs and PFESAs.25 
Given the large number of PFAS and the scarce knowledge about their potential hazards, 
a rapid and reliable method to predict the behavior of these chemicals in the environment and 
organisms would be of great benefit. In our previous work, we developed mechanistic 
physiologically based toxicokinetic (PBTK) models that explicitly consider binding with serum 
albumin, liver-type fatty acid binding protein (LFABP), and organic anion transporters to predict 
the bioaccumulation of PFCAs and PFSAs in different tissues of both fish and rat.81, 82 The success 
of our models demonstrated that the interaction of PFAS with proteins plays an essential role in 
determining their bioaccumulation potential in organisms, and thus could be used as a proxy for 
bioaccumulation assessment. However, the protein binding parameters used to build the models 
were limited to a small subset of PFAS (e.g., PFOA and PFOS).13  
To provide insights into the bioaccumulation potential of novel PFAS and generate more 
protein binding parameters for PBTK models, we proposed an in silico method based on molecular 
dynamics (MD) simulations to predict PFAS-protein interactions. Specifically, we employed the 
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molecular mechanics combined with Poisson-Boltzmann surface area (MM-PBSA) continuum 
solvation method to calculate binding affinities between ligands (i.e., PFAS) and proteins. As a 
starting point, we focused on LFABPs in this study because of their available 3-dimensional crystal 
structures and experimental binding affinity data with different PFAS, which can be used for 
method evaluation. In the MM-PBSA method, the free energy of binding, ΔGbind, for a chemical 
reaction: P + L = PL (P denotes the protein and L the ligand) is calculated from: 
 
 𝛥𝐺𝑏𝑖𝑛𝑑 = 𝐺
𝑃𝐿 − 𝐺𝑃 − 𝐺𝐿 (3-1) 
 
where the free energy of a state (i.e., GP, GL, and GPL) is derived from post-processing an ensemble 
of representative protein-ligand snapshots generated from MD simulations.44 This method is more 
computationally efficient than rigorous alchemical perturbation methods (e.g., free energy 
perturbation and thermodynamic integration methods), but more robust compared to molecular 
docking based on scoring functions.43 It is worth noting that MM-PBSA is a continuum solvation 
method and involves several thermodynamics approximations, which makes the absolute binding 
energies unreliable.43 However, many studies have demonstrated that MM-PBSA is able to 
successfully predict the relative binding affinities of ligands.43, 44, 110-113 Therefore, the primary 
goal of this study is to rank the binding affinities of PFAS bound to LFABPs. Given the large 
number of PFAS, an efficient method like MM-PBSA would be of great benefits. 
In this chapter, we first developed the following MD-based workflow to estimate ΔGbind 
for LFABP-PFAS interactions: the initial structure of the LFABP-PFAS complex was generated 
from molecular docking, a powerful tool to predict the binding mode between a protein and a 
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ligand;114 based on the complex structure, the MD simulation was then carried out; finally, MM-
PBSA was used to calculate the ΔGbind.  
Then to test the power of the MD workflow and apply it to inform bioaccumulation 
potential for alternative PFAS, we considered 15 PFAS with different functional head groups and 
fluorinated carbon chain lengths including 10 legacy PFAS (7 PFCAs: PFBA, PFPA, PFHxA, 
PFHpA, PFOA, PFNA, and 2m-PFOA; and 3 PFSAs: PFBS, PFHxS, and PFOS) and 5 alternatives 
(3 PFECAs: ADONA, GenX, and EEA; and 2 PFESAs: F-53 and F-53B). The 2-dimensional 
structures of these chemicals are shown in the Appendix Figure 4. The binding affinities of these 
chemicals were evaluated for 2 different LFABPs (hLFABP and rLFABP for human and rat 
LFABP, respectively) which have been previously experimentally determined.37, 115, 116  
Finally, we explore the application of the MD workflow in estimating the bioaccumulation 
potential across different species. In this part, we selected LFABPs of 7 species (i.e., human, rat, 
chicken, zebrafish, rainbow trout, Japanese medaka, and fathead minnow) as protein proxies for 
bioaccumulation assessment. The MD workflow was employed to predict the interactions between 
those LFABPs and 9 PFAS with different functional head groups and fluorinated carbon chain 
lengths including (i.e., 6 PFCAs: PFBA, PFPA, PFHxA, PFHpA, PFOA, and PFNA; and 3 PFSAs: 
PFBS, PFHxS, and PFOS). This application could enhance understanding of LFABP-PFAS 
interactions across species and thus can inform research and decision-making. 
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3.2 Materials and Methods 
 
Figure 8. Molecular Dynamics Workflow. 
 
The molecular dynamics workflow was used to estimate the LFABP binding affinity for 
different PFAS. As shown in Figure 8, the workflow consists of four major steps: curation of 
structures, molecular docking, molecular dynamics, and molecular mechanics combined with 
Poisson-Boltzmann surface area (MM-PBSA) calculation. 
3.2.1 Curation of Structures 
The 3-dimensional crystal structures were obtained from the Protein Data Bank (PDB, 
http://www.rcsb.org) for hLFABP (PDB code: 3STM117) and rLFABP (PDB code: 1LFO118). 
These structures were selected because their high resolution and completeness of key residues, as 
discussed in our previous docking study of LFABP interaction with PFAS.119 For LFABP of other 
species, Phyre2120 was used to construct 3-dimensional structures because it is one of the most 
popular protein structure prediction servers and very user-friendly120. The protein sequences used 
to build the 3-dimensional structures are shown in Table 5. We selected the structure with the 
 49 
highest confidence as the output of Phyre2. All protein structures constructed for this study have 
a confidence of 100%.  For PFAS ligands, the 3-dimensional structures of PFOA and PFOS were 
extracted from 5JID (PDB code for crystal structure of human transthyretin in complex with 
PFOA121) and 4E99 (PDB code for crystal structure of human serum albumin in complex with 
PFOS122), respectively. The other 3-dimensional structures were constructed from scratch using 
Avogadro (v1.2.0)123 and exported in pdb file format. 
3.2.2 Molecular Docking 
All PFAS ligands were docked to LFABPs with Autodock Vina (v1.1.2),124 as described 
in our previous study.119 Briefly, both protein and ligand structures produced above were first 
preprocessed using AutoDock Tools (v1.5.6),125 the output pdbqt files were then used for docking. 
For each protein, the binding site boundaries were determined using the Grid menu in AutoDock 
Tools. According to the 3-dimensional structure of rLFABP, the binding cavity is a flattened 
rectangular box (roughly 13 × 9 × 4 Å).118 Since there is no available dimensions for hLFABP and 
LFABP of other species, we assumed those LFABPs have similar binding pocket as rLFABP. For 
rLFABP, although there are two ligands in the binding cavity, they are not independent with each 
other, that is, the secondary binding site (for the ligand in the solvent-accessible location) would 
not exist until the primary binding site (for the ligand buried inside the pocket) is filled; while for 
hLFABP, only one ligand lies in the binding cavity (i.e., the one buried inside the pocket). For 
simplification, we only considered the primary binding site for those LFABPs. The ligands docked 
to the protein were assumed to be in their deprotonated forms, given their low pKa.8, 126, 127 The 
docking experiments output binding free energies and docking poses for each ligand-protein 
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complex. The 3 binding modes with lowest energies (strongest associations) and distinct 
conformations were chosen as initial structures for MD simulations. 
To assess the success of the docking experiment, we redocked the ligands from the 
crystalized complex (i.e., PDB code 3STM and 1LFO) back into their corresponding receptors and 
measured the root-mean-square deviation (RMSD) between original crystal structure and the 
docked ligands using PyMol;128 the results showed that Autodock Vina can successfully predict 
the bound conformations of the ligands and LFABP with reasonable accuracy (RMSD < 2.5 Å). 
In addition, our previous study also demonstrated Autodock Vina can redock PFOS to human 
serum albumin with RMSD smaller than 2 Å.119  
3.2.3 Molecular Dynamics Simulation 
The system setup and simulation of the 90 ligand-protein complexes were performed with 
the Amber 14 suite.129 For system setup, the ff14SB force field130 was used for proteins and the 
general AMBER force field (GAFF)131 was used for ligands. The atomic partial charges of ligands 
were derived by AM1-BCC (AM1-bond charge correction), which is an efficient method to 
reproduce HF/6-31G* RESP charges.132 The whole complex system was explicitly solvated in a 
cubic box of TIP3P water molecules with a minimal distance of 12 Å from solute atoms to box 
edges. Na+ counterions were added to neutralize the systems. Periodic boundary conditions were 
employed for all simulations. Long-range electrostatic interactions were handled by the particle 
mesh Ewald (PME) method.133 The cutoff for nonbonded interactions was set to 8 Å.  
The simulation was carried out by the GPU accelerated pmemd module.134 First, the solvent 
molecules were subjected to 2000 steps of energy minimization, while the solute was constrained 
with the harmonic force constant of 500 kcal mol-1 Å-2 to eliminate nonphysical contact between 
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solute and solvent. Next, the whole system was minimized without restraint for 1500 cycles. Then, 
the system was heated from 0 to 300 K in 20 ps at constant volume; a weak harmonic force constant 
of 10 kcal mol-1 Å-2 was added on the complex. After the heating phase, the density of the system 
was adjusted to 1 g/cm3 at constant pressure (1 bar) for 100 ps with restraint (10 kcal mol-1 Å-2) on 
the complex. Finally, the system was equilibrated at constant temperature (300 K) and pressure (1 
bar) for 2 ns, the temperature was controlled by Langevin dynamics with a collision frequency of 
2 ps-1,129 and the pressure was controlled by the isotropic position scaling protocol.129 Under the 
same condition as in the equilibration phase, the production run for the complex system was 
performed for 24 ns. The SHAKE bond length constraints were used to allow a larger timestep of 
2 fs.135 The trajectories were sampled at a time interval of 16 ps to ensure each snapshot is 
statistically independent.43, 136 All simulations were run on an AMBER GPU Certified MD 
workstation (Exxact Corporation, CA, USA). 
3.2.4 MM-PBSA Calculations 
Free energy calculations were conducted using the MMPBSA.py program in Amber 14.44 
Specifically, ΔGbind between PFAS ligands and LFABPs were calculated as follows: 
 
 𝛥𝐺𝑏𝑖𝑛𝑑 = 𝐺
𝐶𝑜𝑚𝑝𝑙𝑒𝑥 − 𝐺𝐿𝐹𝐴𝐵𝑃 − 𝐺𝑃𝐹𝐴𝑆 (3-2) 
 
where GComplex, GLFABP, and GPFAS are the free energies of complex, LFABPs, and PFAS ligands, 




 𝐺 = < 𝐸𝑏𝑜𝑛𝑑 + 𝐸𝑒𝑙 +  𝐸𝑣𝑑𝑤 + 𝐺𝑝𝑜𝑙𝑎𝑟 + 𝐺𝑛𝑜𝑛𝑝 − 𝑇𝑆 > (3-3) 
 
where the brackets indicate an average over MD trajectories. Inside the brackets, the first three 
terms are molecular mechanical energy terms for bonded, electrostatic and van der Waals (vdw) 
interactions, respectively. Gpolar is the polar solvation free energy, which was calculated using the 
Poisson-Boltzmann (PB) implicit solvent method (which is a differential equation based on the 
Poisson continuum dielectric model and Boltzmann distribution for the ions in the solvent).140 
Gnonp is the nonpolar contribution, which was determined from a linear relation to solvent-
accessible surface area. The last term is the absolute temperature (T) multiplied by the entropy (S), 
which was estimated by normal-mode analysis using the nmode program in Amber 14;129 
Specifically, the entropy change is calculated based on the change in three types of molecular 
motions (i.e., translational, rotational, and vibrational motion) of the system when ligand binds to 
the receptor.141 For the thermodynamic variables to control the calculation, the recommended 
values for Amber 14 were employed (e.g., the external and internal dielectric constants are 80.0 
and 1.0, respectively).129 Finally, a single trajectory protocol (STP) approach was used for the free 
energy calculation.44 That is, the calculation of Gcomplex, GLFABP, and GPFAA were based on a single 
MD trajectory of the complex system, rather than on 3 trajectories generated from 3 separate MD 
simulations. We employed STP method based on the following considerations. First, since no 
study is available indicating that the binding of PFAS to LFABPs causes a significant 
conformation change, we assumed the proteins and ligands are comparable in the bound and 
unbound states. Second, all ligands in our study have similar chemical structure (i.e., fluorinated 
carbon chain and functional head group). Finally, The STP method is less computationally 
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expensive, and it also leads to a cancellation of the Ebond term in equation 3, which improves the 
precision of the results tremendously.43, 44 
As described in the MD simulation section, a total of 1500 independent snapshots (24 ns 
production divided by the timestep of 16 ps) were generated for an individual complex system. 
These MD snapshots were evenly divided into 3 groups (i.e., the first 4 ns or 250 snapshots is 
group one, the second 4 ns or 250 snapshots is group two and so forth, each group could be 
considered as an independent simulation phase). In each group, the binding free energy was 
calculated using equation 2 and 3 and then averaged over all snapshots; for the entropy calculation, 
because it is very computationally expensive,44 only 10 snapshots in each group were considered 
for normal-mode analysis. Those 10 snapshots were collected as a subset of the total of 250 
snapshots in each group based on an interval of 25 snapshots. All MM-PBSA calculations were 
carried out on Bridges, part of the Pittsburgh Supercomputing Center (www.psc.edu). 
3.2.5 Free Energy Decomposition 
To gain insights into the contributions to the binding free energy, energy decomposition on 
a per-residue basis was performed using the decomp program in Amber 14.44 The per-residue 
decomposition scheme can decompose calculated free energies into specific residue contributions 
based on the Poisson-Boltzmann implicit solvent model.142, 143 The contribution of each residue in 
LFABP to the total free energy of the complex system was estimated. 
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3.2.6 Data Analysis 
The final binding free energies estimated by MM-PBSA were averaged over 3 MD 
simulation phases and 3 binding modes for each LFABP-PFAS pair (i.e., a total of 9 ΔGbind values 
for each LFABP-PFAS pair). The standard error of the mean was then calculated. Moreover, the 
correlation analysis for predicted free energies versus carbon chain lengths and predicted free 
energies versus experimental binding affinities were conducted. For comparison and correlation 
analysis, the experimental data represented as equilibrium dissociation constant (Kd) with units of 
µM were translated into free energy of binding (ΔGbind, in kcal/mol) as follows:144, 145 
 





where R is gas constant (1.987 cal K-1 mol-1), T is temperature (which is assumed to be 300 K), 
and c0 is the standard state concentration (1 M). 
Finally, one-way ANOVA was conducted to test for significant differences among the 7 
different species of LFABP (i.e., human, rat, chicken, zebrafish, rainbow trout, Japanese medaka, 
and fathead minnow) for 9 PFAS ligands (i.e., 6 PFCAs: PFBA, PFPA, PFHxA, PFHpA, PFOA, 
and PFNA; and 3 PFSAs: PFBS, PFHxS, and PFOS). In addition, multiple comparisons with 
Tukey’s test were performed to identify which groups are significantly different from each other 
for cross-species effects. The Python package SciPy (https://scipy.org/index.html) and statsmodels 
(https://github.com/statsmodels/statsmodels) were used for ANOVA and Tukey’s test, 
respectively; and both tests were conducted based on the 9 different ΔGbind values for each LFABP-
PFAS pair. 
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Table 5. Amino acid sequences for different species. 




























Notes: The sequences can be downloaded from PDB website (https://www.rcsb.org/) for human and rat and from 
NCBI website (https://www.ncbi.nlm.nih.gov/) for other species.  
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3.3 Results 
3.3.1 Method Evaluation 
To evaluate the effectiveness of the MD workflow, we conducted correlation analysis 
between the predicted ΔGbind to the experimental ΔGbind derived from three different studies 
(Figure 9).37, 115, 116 For hLFABP, MM-PBSA performance varied between different experimental 
studies. In comparison with the Sheng et al. study (Figure 10A),116 the correlation coefficient was 
excellent (r = 0.97), while the correlation analysis between computational results and the Zhang et 
al.115 study indicated a coefficient of 0.79 (Figure 10B), which is also acceptable. The binding free 
energies between rLFABP and PFAS ligands from the simulation correlate very well with 
experimental data (Figure 10C, r = 0.96). The results also show that the predicted absolute binding 
energies of PFAS are generally lower than corresponding experimental values. However, it should 
be emphasized that our study is primarily focused on the relative binding affinities of PFAS rather 
than their absolute binding strengths. 
3.3.2 Protein Binding Affinity for Legacy and Novel PFAS 
The MD workflow was used to estimate the protein binding affinity for novel PFAS. In 
this part, the results of the interactions between 15 PFAS (i.e., PFBA, PFPA, PFHxA, PFHpA, 
PFOA, PFNA, 2m-PFOA, PFBS, PFHxS, PFOS, ADONA, GenX, EEA, F-53 and F-53B) and 2 




Figure 9. Correlations between the average ΔGbind calculated by MM-PBSA and the experimental values. 
(A) hLFABP from Sheng et al.,116 (B) hLFABP system from Zhang et al.,115 and (C) rLFABP from Woodcroft 




Figure 10. The interactions between human LFABP and PFAS ligands. 
  
 59 
3.3.2.1 Molecular Docking 
The docking experiment was conducted mainly to predict the interaction between LFABP 
and PFAS to find potential binding modes.114 The interaction structures for the best binding mode 
of each LFABP-PFAS complex for rat and human LFABP are indicated in Figure 10, and 
Appendix Figures 5 and 6. As shown, the interactions between PFAS and the two LFABPs 
(rLFABP and hLFABP) are substantially different. For hLFABP, the residues closely interacting 
with PFAS include ARG 122, SER 39, SER 124, PHE 50, ILE 109, ILE 41, and LEU 91; while 
for rLFABP, the close contact residues consist of ARG 122, TYR 120, MET 74, LEU 28, and TYR 
54 (except for the rLFABP-PFBS interaction, where the close contact residues are ARG 122, SER 
39, and SER 124). With respect to hydrogen (H) bonding interactions (Table 6), all PFAS ligands 
formed H bonding with hLFABP, and most interactions occurred between ligands and residues of 
ARG 122, SER 124, or SER 39. On the other hand, only a few instances of H bonding occurred 
between PFAS ligands and rLFABP, and the major residue participating in H bonding interactions 
is TYR 120. 
In addition, for both LFABPs, the predicted binding modes were similar among ligands 
with different functional head groups (i.e., carboxyl and sulfonate groups). The binding of 
alternative PFAS (which contain ether groups in their structures) and legacy PFAS (which contain 
no ether group) to LFABPs show little difference in terms of conformations. The only notable 
differences were observed for 2m-PFOA and GenX, both of which have branched structures. As 
indicated in Figure 10, the carboxyl group in 2m-PFOA and GenX mainly interacted with THR 
102 and SER 100, not ARG 122, SER 124 and SER 39, which were the major residues interacting 
with the head group of other PFAS. 
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Table 6. The protein residues interacting with the PFAS ligands through H-bond and those having dominant 




Human LFABP Rat LFABP 





PFBA ARG 122, SER 124 ARG 122, SER  39, ILE  52 - SER 57, LYS 58, LYS 32 
PFPA ARG 122, SER 124 ARG 122, VAL  83, PHE  50 - ARG 122, TYR 55, ILE 53 
PFHxA ARG 122, SER 124 ARG 122, SER  39, SER 124 TYR 120 ARG 122, ILE 53, LYS 58 
PFHpA ARG 122, SER 124 ARG 122, SER  39, ILE  52 - ARG 122, ILE 60, MET 74 
PFOA ARG 122, SER 124 ARG 122, SER  39, ILE  52 - ARG 122, TYR 55, ILE 60 
PFNA ARG 122, SER 124 ARG 122, SER  39, ILE  52 - ARG 122, ILE 60, ILE 53 
PFBS ARG 122, SER 39 ARG 122, SER 124, LEU 9 ARG 122, SER 39 ARG 122, SER 100, LEU 71 
PFHxS ARG 122 ARG 122, SER 124, SER  39 - ARG 122, ASN 111, LEU 51 
PFOS ARG 122, SER 124 ARG 122, SER 124, ILE  52 TYR 120 ARG 122, ILE 60, ILE 53 
EEA ARG 122, SER 39 ARG 122, SER  39, ASN 111 - ARG 122, MET 74, ILE 60 
GenX THR 102 ARG 122, ASN 111, THR 73 - ARG 122, MET 74, ILE 53 
ADONA ARG 122, SER 124 ARG 122, SER  39, SER 124 - ARG 122, MET 74, TYR 55 
2m-PFOA SER 100 ARG 122, SER 100, ASN 111 - ARG 122, TYR 120, ILE 60 
F-53 ARG 122, SER 124 ARG 122, PHE  50, SER 39 TYR 120 ARG 122, SER 124, ILE 53 
F-53B ARG 122, SER 124 ARG 122, SER 124, SER 39 TYR 120 ARG 122, TYR 55, ILE 60 
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3.3.2.2 MM-PBSA 
The average ΔGbind calculated based on MM-PBSA and five energy components (i.e., vdw, 
electrostatic, polar and nonpolar solvation energy, and entropy) of each LFABP-PFAS pair for rat 
and human LFABP are present in Appendix Tables 8 and 9. As indicated, the predicted free 
energies of ligands interacting with hLFABP and rLFABP range from -15.76 to -2.21 kcal/mol 
and from -11.26 to -3.74 kcal/mol, respectively. For each ligand, the predicted binding affinities 
with hLFABP are generally higher than that of rLFABP. For both LFABPs, the most significant 
contribution to the binding affinity is the electrostatic interaction, but this large change of 
electrostatic interaction upon binding is compensated by the polar solvation energy. The nonpolar 
solvation energies are very small and show a minor variation among ligands, thus having 
insignificant contribution to the ΔGbind.  
Figure 11 shows the distribution of vdw, the sum of electrostatic and polar solvation 
energy, and entropy changes for each ligand-protein system. The sum of electrostatic and polar 
solvation energy is shown instead of the separate contributions because both energy terms are 
strongly anti-correlated (r = -0.96). An obvious pattern was observed between vdw and carbon 
chain length: as carbon chain length increases, the vdw interaction energy decreases. The entropy 
term also indicated a similar trend, but the relationship is not as strong as vdw. With respect to 
electrostatic and polar solvation energy, wild fluctuations were observed in both LFABP systems. 
In particular, the sum of electrostatic and polar solvation energy for PFHxA bound to hLFABP is 
much lower compared with other ligands. 
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Figure 11. The distributions of the energy components of ΔGbind. 
Those energy components include the sum of electrostatic interactions and polar solvation free energy (ELE + 
PB), van der Waals energy (vdw), and entropy changes upon binding. Pink represents the hLFABP system, 




Figure 12. The distribution of ΔGbind (mean ± standard error) for different LFABP-PFAS complexes and the 
correlation analysis between ΔGbind and carbon chain length. 
Pink represents hLFABP, and blue is rLFABP. 
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A correlation analysis was conducted between predicted ΔGbind and carbon chain length. 
As shown in Figure 12, for both LFABP systems, the ΔGbind indicates negative relationships with 
carbon chain length. A strong correlation is observed for PFCAs versus rLFABP, and PFSAs 
versus both hLFABP and rLFABP, with correlation coefficients of -0.93, -1.0, and -0.72, 
respectively. The correlation for PFCAs versus hLFABP is relatively weak (r = -0.41), and the 
major reason for this is due to the much lower predicted ΔGbind for PFHxA, which can be further 
attributed to the much more favorable electrostatic interaction and polar solvation energy between 
PFHxA and hLFABP (Figure 11). In terms of predicted ΔGbind for novel PFAS, 2 PFESAs exhibit 
comparable or stronger binding affinities than PFOS for both LFABPs. The ΔGbind of EEA and 
ADONA are similar with PFNA when bound to hLFABP, and similar with PFHpA when bound 
to rLFABP, while the ΔGbind of GenX is weaker compared to that of PFHxA, which has the same 
carbon number as GenX. Finally, 2m-PFOA has a comparable binding affinity with PFOA for 
both LFABPs. 
3.3.2.3 Free Energy Decomposition 
The contribution of each residue in the rat and human LFABPs to the binding free energy 
was determined based on a per-residue decomposition scheme. For each residue, all free energy 
components in Equation 3 except entropy and nonpolar solvation energy (the calculation of both 
terms were not available in the decomp program in Amber 14) were calculated. In each LFABP-
PFAS complex system, the residues contributing most to the total free energy were determined 
(they account for 44 % to 85 % contribution among all protein residues). As shown in Table 6, for 
hLFABP the residues such as ARG 122, SER 39, SER 124, and ILE 52 contribute significantly to 
ΔGbind among all ligands, while for the rLFABP system, the residues showing strong contributions 
include ARG 122, ILE 60, ILE 53, TYR 55, and MET 74. 
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3.3.3 Bioaccumulation Potential Across Species 
The MD workflow was employed to probe the bioaccumulation potential across different 
species by examining LFABP interactions across 7 different species (i.e., human, rat, chicken, 
zebrafish, rainbow trout, Japanese medaka, and fathead minnow) for 9 PFAS with different chain 
length and functional groups (i.e., PFBA, PFPA, PFHxA, PFHpA, PFOA, PFNA, PFBS, PFHxS, 
and PFOS). The ΔGbind value were calculated for each LFABP-PFAS complex and analyzed by 
different statistical tools. As shown in Table 7, the average ΔGbind values over the 9 tested PFAS 
ligands for human, rat, chicken, and rainbow trout are smaller than -8.0 kcal/mol. This is a 
substantially lower value (i.e., stronger binding affinity) than that predicted for Japanese medaka 
and fathead minnow (average ΔGbind values larger than or equal to -5.25 kcal/mol, Table 7). The 
binding affinity for zebrafish is between these two groups, with an average ΔGbind value of -6.44 
kcal/mol. A one-way ANOVA shows there is a significant difference across 7 species for all 9 
tested PFAS in terms of their LFABP binding affinity, with P values ranging from 1.02E-10 to 
0.021.  
 
Table 7. The average, max, and min of ΔGbind over all tested PFAS ligands for 7 different species of LFABP. 
LFABPs Max ΔGbind Min ΔGbind Mean ΔGbind 
human -4.39333 -13.9894 -8.89 
rat -4.85333 -10.3439 -8.06698 
chicken -4.89333 -12.9956 -9.2 
zebrafish -3.12778 -10.8956 -6.44444 
rainbow trout -2.01111 -16.2389 -8.45975 
Japanese medaka 2.956667 -12.9867 -3.86617 




Figure 13. Multiple comparison (Tukey test) between human LFABP and other LFABPs for different PFAS. 
Blue is human LFABP; red indicates significant difference (p < 0.05); gray means no difference from human 




Figure 14. Distribution of ΔGbind for different PFAS- LFABP complexes across species. 
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The multiple comparison Tukey test between human LFABP and the LFABPs for the other 
6 species shows that Japanese medaka has significantly weaker LFABP binding affinity compared 
to human for all PFAS ligands (P < 0.05) except PFHxA, PFOA and PFNA (Figure 13). Fathead 
minnow also shows significantly weaker LFABP binding affinity than human for PFBS and 
PFHxS (P < 0.05), while LFABP of other species all indicate comparable binding affinity to human 
LFABP (P > 0.05) for all PFAS. 
Finally, a correlation analysis was performed between ΔGbind and carbon chain length. As 
indicated in Figure 14, in all LFABP systems, a quite strong negative relationship was observed 
for both LFABP versus PFCAs and LFABP versus PFSAs, with the correlation coefficient ranging 
from -0.64 to -1.0. 
3.4 Discussion 
In this study, we developed a workflow combining molecular docking and MM-PBSA 
based on MD simulation techniques to predict the binding affinity of legacy and replacement PFAS 
for LFABPs. Experimental data from three different studies37, 115, 116 were used to evaluate this 
approach, and the performance is excellent for predicting PFAS binding affinity to rLFABP (r = 
0.96). For hLFABP, predictions are different between Zhang et al.115 (r = 0.79) and Sheng et al.116 
(r = 0.97). Both studies used fluorescence displacement assays to measure the dissociation 
constant. However, the binding affinity results (expressed as Kd values in unit of µM) of Sheng et 
al. were 3 to 8 times higher than those of Zhang et al., which reveals the variation among different 
experimental studies. Given that available experimental datasets for LFABP-PFAS complex are 
very small, we call for a broadening work on protein-PFAS interactions which will make validation 
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of the predicted results more reasonable. The available data in those three studies cover most 
traditional PFAS and two novel PFAS (i.e., GenX and F-53B). The satisfactory performance of 
the MM-PBSA method we used demonstrates its ability to rank the binding affinity of both legacy 
and alternative PFAS. 
3.4.1 Protein Binding for Legacy and Novel PFAS 
This approach provided mechanistic understanding of how the molecular structures of 
PFAS influence their protein binding behavior. For legacy PFAS (i.e., PFCAs and PFSAs), as 
carbon chain length increases, the binding affinity also increases. Further analysis for each energy 
component of ΔGbind showed that the strong relationship between carbon chain length and binding 
affinity was mainly caused by the vdw interaction energy and entropy change upon binding, both 
of which indicate a close correlation with carbon chain length (Figure 11). The sum of electrostatic 
interaction and polar solvation energy terms, on the other hand, seem to fluctuate around a certain 
value. The extreme low value for PFHxA bound to hLFABP may be because the simulation time 
is not long enough for hLFABP-PFHxA complex system. To validate this hypothesis, a twice 
longer molecular dynamics simulation was performed for the hLFABP-PFHxA complex. The 
results show that the new calculated average ΔGbind of hLFABP-PFHxA is -5.55 kcal/mol, and 
with the updated ΔGbind, the correlation coefficient for PFCAs versus hLFABP becomes -0.93, 
which is much better than previous results.  
For most alternative PFAS, the addition of ether groups actually increased their binding 
affinities to LFABPs in comparison with their perfluoroalkyl counterparts with same carbon 
numbers. Binding free energy component analysis indicated that introducing oxygen in their 
backbone increases the chain length of PFAS; longer chain length indicates greater vdw 
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interactions with the proteins and more favorable entropy changes (larger molecule has greater 
molecular motions and thus higher entropy),141 therefore, the introduction of ether groups in PFAS 
could lead to a stronger binding free energy (Figure 12). It is interesting to note that distinct from 
other novel PFAS, GenX has a branched structure similar to 2m-PFOA, which imparts some 
special behaviors. Due to its structure, GenX (and 2m-PFOA) showed a significantly different 
binding mode from linear PFAS; instead of interacting with ARG or SER residues, the head group 
of GenX mainly interacted with THR residue through H-bonding (Figure 10). Furthermore, 
although inserting an oxygen atom, the binding affinity of GenX was comparable with or even a 
little weaker than PFHxA (which has the same carbon numbers as GenX). This implies that the 
binding affinity is closely related to the backbone chain length, not the total carbon number 
including branches. 
Our results suggest that EEA and ADONA indicate at least as strong binding strength as 
PFHpA when bound to rLFABP, and as PFOA when bound to hLFABP. For F-53 and F-53B, both 
have similar or stronger binding affinities than PFOS. Based on our toxicokinetics model, these 
alternatives could be as bioaccumulative as legacy PFAS. In addition, toxicological studies of F-
53B have shown a similar or stronger toxicity compared with PFOS,102, 116 and the toxic effect 
(e.g., hepatotoxicity, genotoxicity, and developmental toxicity) of other alternatives were also 
reported and summarized by Wang et al.24 The above bioaccumulation and toxicity results indicate 
that those substances are not necessarily safer alternatives to legacy PFAS, particularly when the 
backbone chain length is greater than 6. 
Given the vast number of PFAS (more than 4000) potentially on the market and our limited 
resources (e.g., time and cost), it is not feasible to evaluate all PFAS individually through 
experimental study.8 Therefore, in silico methods based on computational biology hold great 
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promise for the hazard and risk assessment of non-tested PFAS. The MM-PBSA approach based 
on MD simulation provides reliable protein binding affinity prediction for legacy and alternative 
PFAS, and thus can be used for large-scale screening of protein-PFAS interactions. In addition, 
the binding affinities generated from this approach can be further used as parameters for our 
previous PBTK models, which were developed by considering the interactions between PFAS and 
proteins including serum albumin, LFABPs, and membrane transporters.81, 82 The combination of 
MD simulation and PBTK modeling will provide a flexible framework that can be used to evaluate 
the bioaccumulation behaviors of non-tested PFAS and support their risk assessment. 
3.4.2 Bioaccumulation Potential Across Species 
By estimating PFAS binding affinity to LFABP across different species (i.e., human, rat, 
chicken, zebrafish, rainbow trout, Japanese medaka and fathead minnow), our workflow revealed 
that human LFABP has comparable PFAS binding affinity to all other vertebrate species evaluated, 
except Japanese medaka and fathead minnow. The LFABP of those two fish species indicated 
significantly weaker binding affinities than human for some PFAS ligands (Table 7 and Figure 
13). A closer look at the binding mode of PFAS bound to human, Japanese medaka, and fathead 
minnow LFABP shows that the close contact residues are very similar across those species for 
different PFAS, but the positions of these residues are quite different between human and the two 
fish species (e.g., SER124 versus SER52, Table 8 and Figure 15). It seems that the position of key 
residues, which seem to drive the position of ligand binding, can cause significantly different 
binding affinities between humans and the two fish species. Because the identity, not the position, 
of close-contact residues is conserved (i.e., the residue is a serine in both cases in the example 
above), the specific amino acids are implicated in facilitating certain key interactions (e.g., 
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hydrogen bonding). At the same time, when the position of ligands is closer to the bottom of the 
LFABP binding pocket, the binding affinity also tends to be stronger (Figure 15). Thus, we 
conclude that when the position of key residues facilitate binding in a region of the protein that is 
more energetically favorable (e.g., increases hydrophobic contacts), stronger binding affinities 
result. However, these observations should be tempered with an acknowledgment that molecular 
simulations have a degree of uncertainty and variations in the predictions of exact binding 
conformations can and do occur from simulation to simulation. 
Based on the MD workflow results, human, rat, chicken, zebrafish, or rainbow trout seem 
to be better representative species of the higher range of vertebrate bioaccumulation potential of 
PFAS than Japanese medaka and fathead minnow. It is worth pointing out that this conclusion is 
based on the interaction between PFAS and LFABP. Other proteins such as serum albumin and 
membrane transporters also play important roles in determining the bioaccumulation behavior of 
PFAS 81 and should be included in future work. 
In conclusion, in this Chapter we developed a modeling workflow that combines molecular 
docking and molecular dynamics simulation techniques to estimate the protein binding affinity of 
PFAS. By comparing the model prediction with different experimental data, the MD-based 
workflow has been demonstrated to be an efficient and reliable way to predict the protein binding 
affinity for PFAS. In addition, the MD-based workflow can be successfully used to inform about 
the bioaccumulation potential of replacement PFAS and the bioaccumulation potential of PFAS 
across species. As a critical component of the three-level hierarchical framework for PFAS risk 
assessment (Figure 2), the MD-based workflow provides a robust way to generate large numbers 
of protein-PFAS interaction data, which can be used as parameters for the PBTK model. For 
example, based on the results of Chapter 2.0, the protein-PFAS binding affinity for serum albumin 
 73 
and LFABPs as well as the active transport of PFAS facilitated by membrane transporters are 
critical processes for the tissue distribution of PFAS in biological systems; the parameters related 
to those processes can be derived from the output of the MD-based workflow (i.e., ΔGbind for 
protein-PFAS complex). The combination of MD-based workflow and PBTK modeling will 
provide a flexible framework that can be used to evaluate the bioaccumulation behaviors of non-
tested PFAS and support their risk assessment. A second important component of risk assessment 
is to understand the toxicity of the chemical being investigated. While the first two parts of this 
dissertation focused on the toxicokinetics, the final component considers their toxicodynamics 
through the lens of predicted bioactivity. In next Chapter, we will focus on predicting the 




Figure 15. The PFAS binding poses for human (cyan color), Japanese medaka (orange color) and fathead 
minnow (grey color) LFABP after sequence alignment. 
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Table 8. The hydrogen bond and close contact residues for PFAS ligands bound to different LFABPs. 
Ligands 
Japanese medaka Fathead minnow Human 



































































































































4.0 Using Machine Learning to Classify Bioactivity for 3486 Per- and Polyfluoroalkyl 
Substances (PFAS) from the OECD List 
This chapter is reproduced in part with permission from: 
Cheng, W. and Ng, C. A. Using Machine Learning to Classify Bioactivity for 3486 Per- 
and Polyfluoroalkyl Substances (PFASs) from the OECD List. Environmental Science & 
Technology 2019, 53 (23), 13970-13980. Copyright 2019 American Chemical Society. 
[https://pubs.acs.org/doi/abs/10.1021/acs.est.9b04833] 
 
A recent OECD report estimated that more than 4000 per- and polyfluorinated alkyl 
substances (PFAS) have been produced and used in a broad range of industrial and consumer 
applications. However, little is known about the potential hazards (e.g., bioactivity, 
bioaccumulation, and toxicity) of most PFAS. Here, we built machine-learning-based quantitative 
structure-activity relationship (QSAR) models to predict the bioactivity of those PFAS. By 
examining a number of available molecular datasets, we constructed the first PFAS-specific 
database that contains the bioactivity information of 1012 PFAS for 26 bioassays. Based on the 
collected PFAS dataset, we trained 5 different machine learning models that cover a variety of 
conventional models (e.g., random forest and multitask neural network (MNN)) and advanced 
graph-based models (e.g., graph convolutional network). Those models were evaluated based on 
the validation dataset. Both MNN and graph-based models demonstrated the best performance and 
the average of the best area-under-curve score for each bioassay is 0.916. For predictions on the 
OECD list, most of the biologically active PFAS have perfluoroalkyl chain lengths less than 12 
and are categorized into fluorotelomer-related compounds and perfluoroalkyl acids. 
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4.1 Introduction 
According to a recent Organization for Economic Cooperation and Development (OECD) 
report, there are nearly 5000 PFAS that have been in some way registered and/or produced;7 those 
chemicals can be broadly divided into perfluoroalkyl acids (PFAAs, e.g., perfluoroalkyl carboxylic 
acids), PFAA precursors (e.g., fluorotelomer-based substances) and others (e.g., fluoropolymers).8 
Although many long-chain PFAAs have been phased out due to their public health concerns,24, 25, 
57 the potential hazards (e.g., bioactivity, bioaccumulation, and toxicity) of those alternative PFAS 
remain largely unknown. 
Due to the large number of PFAS involved and our limited resources, it is very difficult to 
evaluate all of them individually through experiments. Therefore, reliable quantitative structure-
activity relationships (QSAR) or other predictive modeling approaches hold great promise to 
address the wide variety of PFAS structures in the environment. Computational methods are able 
to provide valuable insight into the behavior of those chemicals, and thus facilitate high-throughput 
screening and prioritization. In our previous work, we developed a molecular dynamics simulation 
based approach that can successfully predict the protein binding affinity for 15 legacy and 
alternative PFAS;146 PFAS-protein interactions have been demonstrated to be critical factors in 
determining their bioaccumulation potential and could potentially be used as a proxy for 
bioaccumulation assessment.81 Although the molecular-dynamics-based approach is a solid 
method to rank the relative protein binding affinity for PFAS, it is still too computationally 
expensive to handle a large dataset containing over 4000 chemicals, especially when the size of 
the protein of interest is large (e.g., serum albumin) — in such cases, the time it takes to run 
simulations and calculate free energies of binding are much longer.43, 44 
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A promising alternative to molecular-dynamics-guided protein interaction approach  is 
machine learning (ML) based QSAR, which employs ML algorithms to model the relationship 
between physical and biological properties of compounds and their chemical structures.45 It is 
much more cost-effective for dealing with large datasets and has been successfully applied for 
decades in many areas like drug discovery and chemical toxicity predictions.46, 47 In particular, the 
advent of deep learning (DL) has revolutionized many research areas including computer vision, 
speech recognition and computational toxicity.147 For example, in a Kaggle competition on 
molecular property predictions, the winning team employed the DL algorithm and achieved a 
relative accuracy improvement of approximately 15% over a random forest baseline.26 In addition, 
the winner of the Tox21 Data Challenge 2014 also used the DL approach.148 Those successes have 
brought tremendous attention from the academic community to ML. 
In general, building a QSAR model involves three major steps: (i) collecting a training 
dataset (i.e., compounds with measured physical or biological properties), (ii) encoding those 
compounds into chemical descriptors (i.e., the feature of each molecule), and (iii) training the 
model to predict chemical properties based on their descriptors and assessing the model 
performance using a validation dataset.149 Advances in high throughput screening (HTS) 
technologies (which can test hundreds to thousands of chemicals simultaneously) have produced 
a tremendous amount of assay data. For example, PubChem’s BioAssay database contains 1 
million bioassays for 96 million compounds. Each bioassay contains a collection of biological 
activity data (e.g., active or inactive) that are determined by testing against biological targets (e.g., 
genes, proteins, or cell lines) in in vitro experiments (https://pubchem.ncbi.nlm.nih.gov/). Such 
extensive databases are ideal for use as training datasets for the first step of QSAR development. 
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For the second step (encoding compounds), molecular featurization is also a well-studied 
problem and various approaches of encoding molecules into fixed-length vectors or mathematical 
graphs have been developed, such as extended-connectivity fingerprints (ECFP)150 and molecular 
graph convolutions.151 Once chemical descriptors have been computed, ML models can be trained 
to make predictions on chemical properties. 
There are a number of QSAR models that have been developed to predict different 
biological or physical properties of PFAS such as interfacial adsorption coefficients,152 interactions 
with transthyretin (which is a thyroid hormone transport protein),153, 154 oral155 and inhalation 
toxicity156 and PFAS mixture toxicity.157 However, all those studies only focused on a single 
bioassay and their PFAS dataset are also very small (ranging from 24 to 58). In addition, those 
QSAR models were built using simple multiple linear regression method and did not consider the 
state-of-the-art ML algorithms such as neural network,158 let alone the more advanced graph-based 
models. To handle the 4730 PFAS in the OECD report, more powerful QSAR models are needed.  
The goal of this study is to develop powerful ML-based QSAR models to predict the bioactivity 
for those PFAS in the OECD list. Specifically, our work makes three major contributions: 
(1) We construct the first PFAS-specific database for QSAR modeling. The PFAS dataset 
contains the bioactivity information of 1012 PFAS for 26 bioassays and was gathered from the 
curated datasets in MoleculeNet,151 a benchmark collection for molecular machine learning that 
includes chemical property information for over 700 000 compounds.  
(2) Based on the collected PFAS dataset, we trained and evaluated the performance of 5 
different ML models that covers a variety of conventional models, including logistic regression,159 
random forests,160 and multitask neural networks158 (one of the deep learning algorithms), and also 
advanced graph-based models, including graph convolutional models161 and weave models.162  
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(3) Using the models with the best performance for each bioassay, we predicted the 
bioactivity of the PFAS in the OECD report and analyzed the patterns in activity and PFAS 
structural features that emerged from the prediction results. 
4.2 Methods 
4.2.1 Original Data Sets 
Table 9. Summary of original datasets obtained from the MoleculeNet benchmark. 
* Active rate means the percent of bioactive chemicals for an assay. The average of the active rate across all assays in 
each dataset is shown. Inside the parenthesis, the minimum and maximum active rates for each dataset are indicated.  
 
The general workflow of ML-based QSAR construction and application to PFAS is shown 
in Figure 16. To the best of our knowledge, there is no PFAS-specific database currently available 
for QSAR modeling. In order to build such a dataset, we focused on a total of 6 different datasets 
including PubChem’s BioAssay (PCBA),163 the Maximum Unbiased Validation (MUV),164 the 
human β-secretase 1 (BACE),165 Blood-brain barrier penetration (BBBP),166 and Toxicology in 
the 21st Century (Tox21) datasets.167 All these datasets have been curated and incorporated into 
the MoleculeNet benchmark (See Table 9 for summary information) and thus can be accessed 
Datasets # Molecules # Bioassays # Bioactivities Active rate (%)* 
PCBA 437929 128 34017170 1.389 (0.009 - 33.124) 
Tox21 7831 12 77946 7.521 (2.884 - 16.152) 
MUV 93087 17 249886 0.196 (0.163 - 0.205) 
BACE 1513 1 1513 45.671 
BBBP 2050 1 2050 76.439 
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through MoleculeNet.151 Briefly, PCBA is a small subset of the PubChem BioAssay database and 
includes 128 bioassays for over 400 thousand compounds;163 MUV is also selected from PubChem 
BioAssay database and is designed for validation of virtual screening tasks using a refined nearest 
neighbor analysis method, the MUV minimizes the effect of the dataset bias (e.g., analogue bias 
and artificial enrichment) on validation results;164 BACE is a membrane-bound aspartyl protease 
that plays a key role for brain amyloid β accumulation and thus is considered as potential drug 
target for Alzheimer’s disease,168 the BACE dataset provides BACE binding results for 1513 
compounds;165 BBBP includes the blood-brain barrier permeability properties for over 2000 
chemicals;166 and Tox21 contains toxicity measurements for 7831 compounds for 12 receptor 
targets including stress response pathways and nuclear receptors.167 In addition, the bioassays for 
all datasets are qualitative: bioactivity results are binary, with a label of 1 meaning active and 0 
meaning inactive. In other words, each bioassay can be considered as a binary classification task. 
Finally, all compounds in those datasets are uniquely identified by their Simplified Molecular 
Input Line Entry System (SMILES) strings, which can be encoded into more sophisticated 





Figure 16. Workflow of machine-learning-based QSAR construction and application to PFAS. 
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4.2.2  Constructing CF and C3F6 Data Sets 
Table 10. Summary of all datasets after -CF- screening process. 
* Active rate means the percent of bioactive chemicals for an assay. The average of the active rate across all assays in 
each dataset is shown. Inside the parenthesis, the minimum and maximum active rates for each dataset are indicated.  
 
Based on the SMILES strings, we first searched each dataset for compounds containing at 
least one -CF- moiety. The summary information for each screened dataset is shown in Table 10. 
We then merged all the reduced datasets into a single CF dataset, which includes 159 bioassays 
for 62043 molecules. This is the broadest set of fluorine-containing compounds we consider, which 
includes many compounds that would not be considered PFAS based on the current definition (i.e., 
-CnF2n+1-). The major goal of constructing the CF dataset is to use it for data augmentation169 
during the ML model training process.  To build a PFAS dataset, we then followed the screening 
criteria in the OECD report and searched the CF dataset for the substances that contains a 
perfluoroalkyl moiety with three or more carbons (i.e., -CnF2n-, n >= 3) or a perfluoroalkyl ether 
moiety with two or more carbons (i.e., -CnF2nOCmF2m-, n and m >= 1).7 After this filtering process, 
the generated dataset, which is referred as the C3F6 dataset, contains 159 bioassay results for 1012 
molecules. For many bioassays in the C3F6 dataset, the bioactivity information was either not 
available or the active rate (i.e., the number of active results divided by the total number of 
Datasets # Molecules # Bioassays # Bioactivities Active rate (%)* 
PCBA 60559 128 4465740 1.237 (0.002 - 51.415) 
Tox21 524 12 4759 9.666 (3.363 - 23.438) 
MUV 7756 17 16594 0.211 (0.077 - 0.463) 
BACE 761 1 761 56.636 
BBBP 285 1 285 91.228 
CF 62043 159 4488139 1.257 (0.002 - 91.228) 
C3F6 1012 26 14335 7.276 (2.038 - 43.000) 
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bioactivities) was very low. To make our models more robust to random splitting, we added 
another filtering criterion to screen for the bioassays that contain at least 50 bioactivity results and 
have an active rate not smaller than 0.02. After this step, the final C3F6 dataset includes 26 
bioassay results for 1012 compounds. 
4.2.3 Machine Learning Models 
We selected 5 different ML models including both conventional methods (i.e., logistic 
regression (LogReg), random forest (RF), and multitask neural network (MNN)) and graph-based 
methods (i.e., graph convolutional model (GC) and weave model) to conduct the QSAR task for 
the C3F6 dataset. Those models were selected because they had the best performance on the 
original datasets in the MoleculeNet (those models were evaluated on the test dataset generated 
from splitting methods).151 For this study, we did not include the Kernel-based support vector 
machine (KernelSVM), which is one of the most widely used ML methods.170 This is because in 
a preliminary test, the KernelSVM did not perform well on the small PFAS dataset (Appendix 
Table 10) and was too computationally expensive to train on the large CF dataset. 
A brief description of the ML models follows:  
(1) LogReg is a simple classification technique that applies the logistic sigmoid function 
to weighted linear combinations of the input feature vectors and output binary prediction results.159 
The L2 regularization was applied to overcome overfitting problems and increase the 
generalizability of LogReg.171  
(2) RF is a popular ensemble predictive model that consists of a large number of individual 
decision trees. Each tree is trained using a sample with replacement from the training dataset and 
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outputs its prediction results. The final prediction of the full forest is determined by the result of 
each individual tree through majority voting algorithms.160  
(3) Artificial neural network (ANN) is a powerful non-linear model that maps input feature 
vector to output vectors through repeated linear and non-linear transformation operations.158 ANN 
architecture consists of an input layer, an output layer, and a number of hidden layers. In MNN, 
the final hidden layer of the network is attached with M softmax classifiers (which is a 
classification model that employs the softmax function, also known as normalized exponential 
function, to predict the probability for each class label), one for each bioassay task (M is the total 
number of bioassays). This architecture makes MNN able to make predictions for multiple 
bioassays simultaneously. For this study, we evaluated the performance of two different MNN 
architectures: one is the Pyramidal MNN (P-MNN), which contains two hidden layers, the first 
layer has 2000 neurons and the second one has 100 neurons;158 the other one contains only one 
hidden layer with 1500 neurons (1-MNN). P-MNN demonstrated the best performance in a recent 
virtual screening task, while the 1-MNN is the default MNN model in the MoleculeNet 
benchmark.151 
(4) GC is a graph-based model where the molecules can be modeled as mathematical 
graphs (i.e., atoms represent nodes, and bonds are edges).161 In GC, the molecules are first 
transformed into molecular graph representations, as described in the Featurization section below. 
Then a number of graph convolution modules (which include graph convolution, batch 
normalization and graph pooling operations) are sequentially operated on the initial molecular 
graph. Finally, a graph feature vector is generated by summing up the feature vector of all atoms 
and then fed to a classification or regression layer.161 
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(5) Similar to GC, weave architecture is another graph-based model.162 The main difference 
is the convolutional operation. In weave module, the atom feature vectors are updated by 
combining information from not only other atoms but also their corresponding pairs in the 
molecular graph. Adding the pair features makes the weave model more efficient at forwarding 
information between atoms; however, it also increases the complexity of weave models. In weave 
models, a number of weave modules (which take atom and pair feature vectors as inputs and output 
a new set of atom and pair features) are stacked in series and followed by a graph gather layer that 
combines atom features into molecule-level features. Finally, the molecular features are fed to a 
classification or regression layer.162 
4.2.4 Featurization 
A total of 3 molecular featurization methods were employed: extended-connectivity 
fingerprints (ECFP), graph convolutions and weave featurization. ECFP are very popular 
molecular characterizations in cheminformatics and were used in LogReg, RF, and MNN models 
to encode the SMILES strings into fixed-length vectors.150 ECFP are circular topological 
fingerprints that work by hashing the fragments of the molecule into a fixed-length binary 
fingerprint. Those fragments represent the circular neighborhood of each atom up to a determined 
diameter.150 ECFP are most commonly used with a diameter of 4 (i.e., ECFP4), and ECFP4 were 
employed in our study. Graph convolutions and weave featurization can encode the molecule into 
a molecular graph and were used here for the GC and weave models, respectively. In both methods, 
an initial feature vector is computed for each atom (node) based on its local environment, such as 
the atom-types, hybridization and valence structures.151 However, these methods are different in 
terms of the connectivity information: graph convolution calculates a neighbor list to represent the 
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connectivity of the whole molecule, while weave featurization utilizes more detailed pair feature 
vectors to represent connectivity information about any pair of atoms in the molecule.151  
4.2.5 Training and Evaluation 
In this study, the C3F6 dataset was randomly split into 70% for the training set and 30% 
for the validation set. The training set was used to train ML models, and the validation set was 
used to tune hyperparameters and evaluate the performance of each model. During the training 
process, in addition to using just the training set, we also applied the data augmentation technique 
by including the whole CF dataset for training.169 The model performance for those two training 
scenarios were compared. Given all bioassays in the datasets are classification tasks, the area under 
the curve (AUC) of the receiver operating characteristic (ROC) curve was used as the performance 
metric and the mean AUC-ROC score over all tasks was reported.172 Following the procedure in 
the MoleculeNet benchmark paper,151 the random split was performed 5 times with different 
random seeds, and the final performance results for different ML models are the average of the 5 
independent runs. 
4.2.6 Hyperparameter Optimization 
The hyperparameters for each ML model are indicated in Appendix Table 11. Both grid 
search and Bayesian optimization with Gaussian process techniques were employed to tune the 
hyperparameters for both CF and C3F6 datasets. For grid search, a range of values were 
considered, and the best hyperparameters were determined based on the mean AUC-ROC score 
on the validation set. For Bayesian optimization, the Matérn kernel and the expected improvement 
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algorithm were selected as the covariance function and the acquisition function,173 respectively, to 
maximize the mean AUC-ROC score for the validation set. After 20 iterations, the optimized 
hyperparameters were determined, as indicated in Appendix Table 11. For some models such as 
the RF and GC, the training process was much more computationally expensive for the large CF 
dataset than the C3F6 dataset. Given our limited resources, we only tuned the hyperparameters 
using the small C3F6 dataset. For the large CF dataset, we directly applied those optimized 
hyperparameters from C3F6 dataset. 
4.2.7 Prediction on OECD Data Set 
After hyperparameter optimization, we selected the ML model that demonstrated the best 
performance on each individual bioassay to make a prediction on the OECD dataset.7 Although 
there are 4730 PFAS listed in the OECD database, only 1213 of them have SMILES string 
information. Therefore, we utilized the CIRpy package (https://github.com/mcs07/CIRpy), a 
Python interface for the Chemical Identifier Resolver, to convert the chemical name of the 
remaining PFAS to SMILES strings. Unfortunately, only a total of 3486 PFAS names (including 
those 1213 PFAS with available SMILES strings) could be successfully converted to SMILES 
strings in this way; for the other PFAS, their SMILES representations were not available in CIRpy 
(the resolver returned None for those chemicals). Our model predictions are based on this final 
processed OECD dataset containing 3486 individual substances. The overview of those PFAS, 





Figure 17. Overview of 3486 PFAS in processed OECD dataset. 
The dataset is grouped based on (A) 8 different structural categories (as defined in the OECD list); (B) 
different perfluoroalkyl chain length (e.g., [6, 12] means the chain length is larger than or equal to 6 and 
smaller than or equal to 12); and (C) categorization as linear vs. nonlinear, polymer vs. non-polymer, or 
PFAA precursor vs. non-precursor, shown as orange vs. green in each case.  
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4.2.8 Applicability Domain (AD) 
The distance-based method was employed to determine the AD of the QSAR models.174 
Specifically, the Euclidean distances between the test compounds (i.e., the PFAS in the OECD 
list) and a defined point (i.e., the centroid) within the descriptor space of the training dataset (i.e., 
the CF dataset, which is the dataset used to train the QSAR models) were first calculated. Then 
the distance from each test compound to the defined point was compared with a pre-defined 
threshold. If the distance of a test compound is smaller or equal to the threshold, the compound is 
considered to be within the AD. A total of 5 different strategies were used to define the threshold 
value, as described in the Sahigara study.174 Briefly, a distance vector was first generated to stores 
the distance between each compound in the training dataset and the centroid of the training dataset. 
The first threshold was based on the maximum distance of the vector (maxdist), The second and 
third threshold values were 2 and 3 times of the average distance of the vector (2*avg and 3*avg), 
respectively. The fourth strategy considered the 95 percentiles (p95) of the vector (sorted in 
ascending order) as the threshold. The last method took the average (avg) and standard deviation 
(std) of the vector into consideration and defined the avg + std * z (z is a parameter and set to 0.5 
as default175) as the threshold. 
4.2.9 Computational Resources and Packages 
All models were run on the Google Cloud Platform (https://cloud.google.com/) or using 
resources from the University of Pittsburgh Center for Research Computing (https://crc.pitt.edu/). 
For conventional ML models (i.e., LogReg, RF, MNN), a virtual instance was created with 8 
CPUs, 30 GB memory and 50 GB disk size; while for graph-based models, a virtual instance with 
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1 NVIDIA Tesla P100 GPU, 4 CPUs, 15 GB memory, and 100 GB disk was established. In 
addition, all ML models were constructed with the DeepChem package 
(https://github.com/deepchem/deepchem), an open-source library that provides high-quality 
implementation of various ML models as well as many useful functions for molecular 
featurization, dataset splitting, and metric calculation. For hyperparameter optimization, we chose 
the pyGPGO package,176 which contains all the functions we need and is easy to implement. 
4.3 Results and Discussion 
The overview of the 3486 PFAS in the processed OECD list, including their structure 
category, perfluoroalkyl chain length, and other features, is shown in Figure 17. Fluorotelomer-
related compounds are the most dominant structures, followed by PFAA precursors and related 
compounds (perfluoroalkyl ones) and perfluoroalkyl carbonyl compounds. The fluoropolymer 
structure category has the smallest numbers of structures (only 2). In terms of perfluoroalkyl chain 
length, most PFAS have a chain length less than 12, while the PFAS with chain length larger than 
18 are very rare (only 31 in total). Most PFAS present belong to the groups of linear isomers, non-
polymers, and potential precursors to PFAAs in the environment/biota. Finally, it is interesting to 
note that among those 3486 PFAS, only 11 of them were also found in the curated C3F6 dataset 
(which contains 1012 chemicals). Given that the C3F6 dataset was generated based on the same 




Figure 18. Training and validation AUC-ROC scores of different machine learning models for C3F6 and CF 
dataset. 
Those models include LogReg (logistics regression), RF (random forest), 1-MNN (multitask neural network 
with 1 hidden layer), P-MNN (pyramidal multitask neural network with 2 hidden layers), and GC (graph 
convolutional model). Error bar indicates 95% confidence interval of the mean. 
 
The performance of different ML models on both training and validation sets is shown in 
Figure 18 and Appendix Table 10. As a reminder, the CF dataset is the large dataset that contains 
at least one -CF- moiety, while the C3F6 dataset is a small subset of the CF dataset and contains 
either a perfluoroalkyl moiety with three or more carbons or a perfluoroalkyl ether moiety with 
two or more carbons. For all models, the average AUC scores over all tasks on training sets were 
substantially larger than that on validation sets, indicating that overfitting is a general problem. 
The reason for the overfitting issue could be that the training dataset is not large enough. To address 
this issue, more PFAS-related bioassay data is needed. For the C3F6 dataset, the GC weave and 
P-MNN models demonstrated better performance than other models. When trained on the CF 
dataset, all models showed a substantial performance boost compared to those trained on the C3F6 
dataset. This illustrates that obtaining more data is of critical importance in improvement of the 
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predictive power of ML models. The best model for the large CF dataset is 1-MNN, which 
achieved the average AUC score of 0.821 over all tasks. 
It is not surprising that MNN demonstrated the best performance for PFAS QSAR tasks, 
especially when a large amount of training data was provided. MNN has been reported to 
outperform traditional models on many Big Data-based QSAR tasks.148, 149, 158 In addition to the 
strength of the deep neural network architecture, the multi-task learning paradigm plays a critical 
role in the performance enhancement of MNN models. By incorporating multiple tasks into the 
learning process, multi-task network could facilitate feature information sharing between different 
tasks and thus benefit some tasks with limited or imbalanced training data.148, 149, 158 In our 
application, the GC model indicated comparable performance to MNN. As discussed in the 
Methods section, GC is based on graph convolutional architecture, which processes molecules as 
mathematical graphs and constructs features with convolution layers. In contrast to fingerprint-
based featurization methods (e.g., ECFP), graph convolutions take greater advantage of the 
information in molecular graphs and provide a flexible way to learn new molecular features.162 A 
number of studies have shown that the learnable feature extracting architectures either outperform 
or perform competitively with traditional ML models.162, 177, 178 As a more sophisticated graph 
convolution-based model, the weave model, however, did not perform well on the CF dataset. The 
main reason is that the weave model is very computationally expensive to train (more than 10 
hours on a GPU platform). Given our limited resources, we only conducted optimization for a few 
hyperparameters within a small range (Appendix Table 11) for the weave model. We expect a 
significant boost in the performance of the weave model could be achieved with a more thorough 
optimization process. 
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Table 11. ROC-AUC scores for different machine learning models. 
 
  
Target Class Target Best Models 
Best AUC-ROC 
Scores 
GPCR NPSR 1-MNN 0.888 
GPCR GLP-1 P-MNN 0.923 
ion channel CNG P-MNN 0.858 
miscellaneous DNA re-replication 1-MNN 0.902 
other enzymes ALDH1A1 1-MNN 0.986 
other enzymes G9a 1-MNN 0.890 
other enzymes CYP2C9 GC 0.988 
other enzymes CYP3A4 GC 0.910 
other enzymes CYP2D6 1-MNN 0.764 
promoter ELG1 P-MNN 0.919 
promoter ATXN 1-MNN 0.969 
protein kinase Plk1 PBD GC 0.753 
protein-protein interaction K18 1-MNN 0.985 
protein-protein interaction HTTQ103 P-MNN 0.950 
protein-protein interaction JMJD2A GC 0.902 
signaling pathway Gsgsp GC 0.992 
transcription factor VP16 1-MNN 0.950 
transcription factor ROR gamma P-MNN 0.950 
transcription factor Nrf2 1-MNN 0.959 
transcription factor Smad3 1-MNN 0.928 
viability HT-1080-NT GC 0.913 
viability DT40-hTDP1 1-MNN 0.888 
viability DT40-hTDP1 1-MNN 0.898 
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The outstanding performances of MNN and GC models demonstrated their capability to 
estimate the bioactivity for PFAS. We therefore applied the well-trained (with CF dataset) 1-MNN, 
P-MNN, and GC model to make predictions on the bioactivity of the PFAS in the processed OECD 
substance list. Here, instead of applying directly the model with the highest average AUC score 
(i.e., 1-MNN) for all bioassays, we compared the performance of the models on each individual 
bioassay and selected the best one to make the prediction for each bioassay. The best model and 
corresponding AUC score for each task (i.e., biological target) are shown in Table 11. The average 
of the best AUC score across all bioassays was 0.916, which is much higher than the average AUC 
score of the single 1-MNN model. Finally, the prediction results for PFAS from the OECD dataset 
were analyzed. 
Figures 19-20 and Appendix Figures 7-9 summarize the bioactivity of the 3486 PFAS in 
the processed OECD dataset. It is important to point out that the 26 targets in our originally 
compiled data set were chosen because they had available PFAS-related bioactivity data. Many of 
the targets were developed specifically for drug discovery (e.g., Marburg virus, orthopox virus, 
and cancer cell viability, see Appendix Table 12), not to identify toxic contaminants. Because 3 of 
the original 26 assay targets pertain to viruses, we focus here on the results for the 23 assays of 
more direct relevance to human or animal cells (detailed descriptions for all 26 targets are provided 
in Appendix Table 12). Each figure represents an individual categorization element (e.g., the 
structure and the chain length) that the PFAS were grouped into. As shown, the most significantly 
affected target class is cell viability, the active rate of PFAS for this target class ranges from 10.8% 
to 60.4%. A fairly large number of PFAS could inhibit the cellular growth of HT-1080-NT 
fibrosarcoma and chicken DT40 cell lines. However, it should be emphasized that those bioassays 
are related to cancer cell, which is different from normal human cells. Other targets significantly 
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affected by PFAS (active rate >≈ 10%) include HTTQ103 (Huntington protein with 103 
polyglutamines expansion) aggregates,179 ROR (retinoic acid-related orphan receptor) gamma,180 
G9a (histone methyltransferase) enzyme,181 and GLP-1 (glucagon-like peptide-1) receptor.182 
Briefly, HTTQ103 aggregation is closely related to neurodegenerative disorders like Huntington's 
disease;179 ROR gamma is a transcription factor that plays a critical role in the differentiation of T 
helper 17 (Th17) cells, which are considered as the major inflammatory cells in autoimmune 
diseases;180 G9a is histone methyltransferase that catalyzes the mono- and di-methylation of 
histone H3 lysine 9 (H3K9) and has been detected to be upregulated in cancer cells;181 GLP-1 
receptor is a Family B G protein-coupled receptor (GPCR) and is a potential therapeutic target for 
type 2 diabetes.182 Those active PFAS could reduce the HTTQ103 aggregate formation, inhibit 
ROR gamma and G9a activity, and bind to GLP-1 receptor. However, the similar bioactivity of 
those PFAS to drugs could still pose potential threats to human health. For example, those PFAS 
might compete with the real drugs for binding to therapeutic targets and cause undesirable effects. 
This hypothesis is evidenced by a recent study that PFOA/PFOS could mimic the function of their 
structurally similar fatty acids and activate the uncoupling protein 1 in brown adipose tissue, which 
may lead to a series negative effects such as decreased metabolic efficiency and decreased 
fitness.183 
Most of the PFAS predicted to be biologically active are fluorotelomer-related compounds, 
followed by PFAAs and PFAA precursors. The distribution of different active PFAS structures for 
each target is roughly proportional to their distribution in the processed OECD dataset (Figure 
17A). In terms of perfluoroalkyl chain length, short-chain PFAS (length < 6) and medium-chain 
PFAS (6 <= length <= 12) are dominant classes in both the biologically active PFAS and the total 
PFAS in the OECD substance list. It is interesting to note that for cancer cell viability, the number 
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of active PFAS are very similar between short-chain and medium-chain PFAS, however, the total 
number of short-chain PFAS is almost twice as much as that of medium-chain PFAS (Figure 17B). 
This indicates that medium-chain PFAS are more likely to impair cancer cell viability. Finally, we 
analyzed the chemical structures for those PFAS that indicate bioactivity for at least half of the 26 
targets (Figure 21 and Appendix Figure 10). The screened 26 PFAS all have similar chemical 
structures: at least one benzene ring and the perfluoroalkyl structure with at least three carbons. A 
large portion of those PFAS belong to perfluoroalkyl carbonyl compounds, with the remaining 
PFAS being fluorotelomer-related compounds and PFAA precursors. In addition, 6 of those PFAS 
(CAS Numbers: 77758-84-0, 77758-89-5, 106376-38-9, 106376-37-8, 200862-70-0, 77758-79-3) 
were included in the KEMI (Swedish Chemicals Agency) 2015 report on occurrence and use of 
highly fluorinated substances and alternatives (https://www.kemi.se/global/rapporter/2015/report-
7-15-occurrence-and-use-of-highly-fluorinated-substances-and-alternatives.pdf). It should also be 
pointed out that some of the highly bioactive PFAS have a relatively long carbon chain length (6 
to 8). Given existing concerns about the bioaccumulation and toxicity of long-chain PFAS, 
additional scrutiny to determine whether the production and use of these chemicals should be 
limited is warranted. Finally, many short-chain PFAS (perfluoroalkyl chain lengths of 3, see 
Appendix Figure 10) were classified as bioactive for every target. This emphasizes that short-chain 
PFAS are not biologically inert, further supported by the recently released studies by the National 




Table 12. The applicability domain of the QSAR model based on distance-based approach with different pre-
defined thresholds. 
Notes: maxdist: maximum distance; 2*avg: 2 times the average distance; 3*avg: 3 times the average distance; 
avg+std*z: average distance plus standard deviation multiplying parameter z; p95: 95 percentile 
 
Finally, the applicability domain (AD) of the QSAR models was determined by distance-
based method. Different strategies were used to define the distance threshold. As shown in Table 
12, using the maximum distance and 2 and 3 times the average distance as the threshold, all 3486 
PFAS in the OECD list lie inside the AD. The threshold strategy of avg + std * z indicated the 
narrowest domain, with 162 PFAS outside the AD. Even so, there are still 95.4% PFAS falling 
inside the AD, indicating our models are able to provide reliable predictions for most PFAS in the 
OECD list. 
In this study, we built a PFAS dataset (i.e., the C3F6 dataset) based on available chemical 
bioactivity datasets. With the PFAS dataset, we trained a number of state-of-the-art ML models 
including both conventional models and graph-based models, which were then used to make 
bioactivity predictions for untested PFAS in the OECD database. Given the limited data on the 
bioactivity and toxicity of PFAS, we believe the benchmarking PFAS dataset we created will 
facilitate the development of novel ML-based QSAR methods to predict PFAS properties in a 
more efficient and reliable way. It is worth noting that our current QSAR models are used for 
bioactivity classification only (yes/no for bioactivity) and cannot provide information about 
Strategies Threshold values Number of compounds outside the AD 
maxdist 8.93 0 
2*avg 11.84 0 
3*avg 17.75 0 
avg+std*z 6.20 162 
p95 6.82 33 
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intensity of effect or dose-response. That will be the key in further understanding the impacts of a 
particular compound. In future work, we hope to expand the PFAS dataset to cover a broader range 
of molecular properties. For example, protein binding affinity is a critical factor in determining the 
bioaccumulation of PFAS,81 and thus should be included in the future. In addition, we will conduct 
further hyperparameter optimization for the graph-based models to achieve better performance on 
the PFAS dataset. 
In conclusion, in this Chapter we developed ML-based QSAR models to predict the 
bioactivity of 3486 PFAS in the OECD list. Based on the evaluation on validation dataset, both 
multi-task neural network and advanced graph-based models demonstrated the best performance 
and the average of the best area-under-curve score for each bioassay is 0.916. The ML-based 
QSAR is an important part of the three-level hierarchical framework for PFAS risk assessment 
(Figure 2); although it cannot provide insights into the toxicokinetics and tissue distribution of 
PFAS in biological systems, the ML-based QSAR is very cost-effective and can be used to screen 
large number of PFAS. After the screening process, the molecular dynamics workflow and 
physiologically based toxicokinetic model can be used to predict the toxicokinetics and 
bioaccumulation of the prioritized PFAS in biological systems. In addition, the ML-based QSAR 
can provide quantitative toxicodynamic information for PFAS such as whether the chemical is 
bioactive/toxic or not.   
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Figure 19. Predicted biological activity of all PFAS (grouped by structure categories) in processed OECD 
dataset for the 23 targets. 
Inside the parentheses, the PubChem AID and the target class are indicated. 
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Figure 20. Predicted biological activity of all PFAS (grouped by perfluoroalkyl chain lengths) in processed 
OECD dataset for the 23 targets. 




Figure 21. The chemical structures for PFAS predicted to have biological activity for at least half of the 
targets investigated in this study. 
The chain length of each individual perfluoroalkyl substructure in the PFAS presented here is longer than 3; 




5.0 Summary and Future Work 
5.1 Summary 
To evaluate the potential hazards of PFAS, different in silico techniques were developed 
in this dissertation including permeability-limited physiologically based toxicokinetic (PBTK) 
modeling to predict PFAS distribution and accumulation in the rat, a molecular dynamics (MD) 
based workflow to predict PFAS-protein interactions, and machine learning (ML) based 
quantitative structure-activity relationship (QSAR) models to predict PFAS bioactivity. The 
performance of these models and their application to PFAS risk assessment are summarized as 
follows: 
The permeability-limited PBTK model was successfully used to predict the toxicokinetics 
and tissue distribution of PFOA in male rats. With the help of the hierarchical Bayesian framework, 
not only were the uncertainties of the posterior parameters substantially reduced, but the PBTK 
model predictions also became more robust: with the posterior parameters, most of the predicted 
plasma toxicokinetic (e.g., half-life) and tissue distribution fell well within a factor of 2.0 of the 
experimental data. In addition, the PBTK model could provide insights into the molecular 
mechanisms that result in the observed PFOA toxicokinetics: PFAS-protein binding, membrane 
permeability and active transport. 
The MD-based workflow provides an efficient and reliable way to predict the protein 
binding affinity for PFAS. By comparing the prediction with experimental data, a good correlation 
between predicted free energies of binding and measured binding affinities was observed, with 
correlation coefficients ranging from 0.79 to 0.97. In addition, the MD-based workflow provides 
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mechanistic understanding of how the molecular structures of PFAS influence their protein 
binding behavior. For example, it was observed that as carbon chain length increases, the binding 
affinity of PFAS also increases. Further analysis for each energy component of the free energy of 
binding showed that the strong relationship between carbon chain length and binding affinity was 
mainly caused by the van der Waals interaction energy and entropy change upon binding, both of 
which indicate a close correlation with carbon chain length. Finally, it was demonstrated that the 
MD-workflow can be used to inform about the bioaccumulation potential of replacement PFAS 
and the bioaccumulation potential of legacy and replacement PFAS across species. With respect 
to replacement PFAS, our results suggest that EEA and ADONA are at least as strongly bound to 
rLFABP as perfluoroheptanoic acid (PFHpA), and to hLFABP as perfluorooctanoic acid (PFOA). 
For F-53 and F-53B, both have similar or stronger binding affinities than perfluorooctane sulfonate 
(PFOS). Given that interactions of PFAS with proteins (e.g., LFABPs) are important determinants 
of bioaccumulation potential in organisms, these alternatives could be as bioaccumulative as 
legacy PFAS, and are therefore not necessarily safer alternatives to long-chain PFAS. For 
bioaccumulation potential across species, humans, rats, chickens and rainbow trout had similar 
binding affinities to one another for each PFAS, whereas Japanese medaka and fathead minnow 
had significantly weaker LFABP binding affinity for some PFAS. This result indicates that 
humans, rats, chicken, zebrafish and rainbow trout seem to be better representative species of the 
higher range of vertebrate bioaccumulation potential of PFAS than Japanese medaka and fathead 
minnow. 
Finally, the ML-based QASR models, built on the first PFAS-specific bioassay database 
constructed in this work, showed good performance. Both multitask neural network and graph-
based models demonstrated the best performance and the average of the best area-under-curve 
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score for each bioassay is 0.916. For predictions on the OECD list, most of the PFAS predicted to 
be biologically active are fluorotelomer-related compounds, followed by PFAAs and PFAA 
precursors. In terms of perfluoroalkyl chain length, short-chain PFAS (length < 6) and medium-
chain PFAS (6 <= length <= 12) are dominant classes in both the biologically active PFAS and the 
total PFAS in the OECD substance list. 
As indicated above, the PBTK, MD-based workflow and ML-based QSAR models form a 
three-level hierarchical framework that has the potential to revolutionize risk assessment for PFAS 
by enabling fast in silico prediction of their bioaccumulation and toxicity and providing insights 
into the toxicokinetics and tissue distribution of those chemicals in biological systems. 
Specifically: 
(1) Our models will relate external measures of exposure (e.g., concentration of PFAS in 
air, food, or water) to internal measures of biologically effective dose (e.g., concentration of PFAS 
in the tissue showing the toxic effects), and thus allow for more realistic internal dose-based 
exposure assessment. 
(2) The parameterization strategies for these models substantially reduce reliance on in vivo 
animal data by making use of in vitro and in silico data sources in innovative ways. Moreover, our 
work will provide a more efficient protocol for risk assessment of large numbers of PFAS in a 
short time. 
(3) Our models will allow for extrapolation of dosimetry among different exposure 
scenarios and animal species, as well as between healthy and susceptible groups, if the relevant 
physiological properties of the target population are available; this is very useful for estimating 
PFAS toxicokinetics in some species where in vivo data is very scarce (e.g., humans). It can also 
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be used to account for interindividual variability by defining the distributions for physiological 
and physiochemical parameters. 
Therefore, our models will play essential roles in enabling new toxicity-testing paradigms 
for assessing risks posed by PFAS. 
5.2 Future Work 
Due to limited data availability for model parameters, the PBTK model was only tested for 
the toxicokinetics of PFOA in male rats. In the future, to generalize the framework to other PFAS 
and other species including humans, more protein-PFAS interaction data are needed. In addition 
to in vitro techniques such as fluorescence spectroscopy37, equilibrium dialysis38, and NMR39 to 
measure protein binding affinity, the MD-based workflow provides an efficient way to estimate 
the protein binding affinity for a large number of PFAS. However, it should be pointed out that 
the values generated from the MD-based workflow are relative protein binding affinities for PFAS. 
This is because the molecular mechanics combined with Poisson-Boltzmann surface area (MM-
PBSA) energy calculation method in the workflow involves several thermodynamic 
approximations for the purpose of computational efficiency43 and thus the estimated free energy 
of binding values cannot be used directly as parameters. Two ways are proposed to deal with this 
issue. First, a relationship between MD-predicted parameter values and the actual values can be 
established using linear regression techniques based on the available in vitro experimental data 
and their MD-predicted values. Then the regression model can be used to estimate the actual values 
for those protein-PFAS interaction parameters that are not experimentally measured. Another way 
is to employ more rigorous method such as thermodynamic integration (TI) technique to estimate 
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protein binding affinity for PFAS. TI is a theoretically rigorous method used to calculate free 
energy differences between two given states (e.g., bound and unbound state) based on a non-
physical thermodynamic cycle;184 although TI is more computational expensive compared to MM-
PBSA, it has shown excellent accuracy in binding free energy prediction.184 Both of those methods 
are worth exploring in the future work given the essential roles of the protein-PFAS interactions 
in the toxicokinetics model development for PFAS. 
In addition, alternative methods to the Markov chain Monte Carlo (MCMC) simulation can 
be used for the Bayesian analysis of the PBTK model. MCMC is a powerful method to generate 
the posterior distribution of model parameters; however, it is not suitable for handling sequentially 
generated experimental datasets due to computational cost.185 If new experimental data for PFAS 
toxicokinetics are available, to include those datasets for Bayesian inference, the previously 
estimated posterior parameter distribution cannot be reused and a new MCMC simulation must be 
conducted.185 To make the Bayesian inference more cost-effective, we can employ the sequential 
Monte Carlo or particle filtering (PF) method, which is a simulation-based method that can be used 
to perform on-line estimation for posterior distributions of interest.186 In PF, the importance 
sampling technique is employed to calculate the importance weights for each sample (i.e., particle) 
and then the samples with the least weights are filtered out.186 When new data arrive, PF would 
update the estimation of the posterior distribution based on only the new data (no need to 
reconsider the old data), which makes PF very efficient to handle the sequential dataset.185, 186 In 
the future, the Bayesian analysis with PF simulation can be tested for the PBTK model to improve 
the model performance. 
Finally, for ML-based QSAR models, a more rigorous data splitting technique for model 
training and evaluation could improve the rigor of the approach. In the current ML model 
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development, the dataset was split into 70% for training and 30% for validation and the validation 
set was used for both hyperparameter tuning and model evaluation. It is suggested that the dataset 
used for model evaluation need to be completely separated from other datasets to avoid any bias 
error caused by the test dataset.187 In the future, to provide unbiased evaluation for the ML models, 
a more rigorous method should be applied to split the dataset into 70% for training, 15% for 
validation and 15% for testing. The validation is then used for hyperparameter optimization, and 
the test set for model evaluation.   
The National Research Council’s report, Toxicity Testing in the 21st Century, proposes a 
shift from in vivo animal tests to in vitro assays and in silico approaches.27 Under this paradigm 
shift, more and more high throughput in vitro assays and sophisticated computational tools are 
used for chemical risk assessment by regulatory agencies. For example, the Tox21 program, a 
collaborative work between United States Environmental Protection Agency (EPA), National 
Center for Advancing Translational Sciences (NCATS), and National Toxicology Program (NTP), 
has generated over 100 million data samples for around 8500 chemicals with high throughput 
screening technology.188 Based on those large toxicological data sets, advanced computational 
tools including mechanistic modeling (e.g., toxicokinetics model) and statistical modeling (e.g., 
machine learning-based QSAR) have been developed to inform chemical risk assessment.189, 190 
These in vitro assays and in silico methods hold great promise to tackle the PFAS management 
issue more efficiently. In vitro assays can be used to generate a large number of toxicity data with 
high throughput technology as well data for the parameterization of toxicokinetic models for PFAS 
(e.g., protein binding affinities). In addition, advancements in computing hardware and algorithms 
could enhance the predictive power of those in silico tools and reduce the computational costs of 
applying those models. With enough data and more advanced models, the toxicokinetics, 
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bioaccumulation and toxicity of PFAS can be predicted in a more efficient and robust way, which 
could substantially improve the risk assessment of PFAS. 
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Appendix A Supporting Information for Chapter 2.0 
Appendix A.1 PBTK Model Parameters 
For rat physiology, most model parameters are representative mean values of the mean 
value reported in different studies.191 In addition, our PBTK model was evaluated on experimental 




Appendix Table 1. Physiological parameters a generic for male rat. 
 
  
 Blood Liver Kidney Gut Muscle Adipose Rest of Body 
Fractional Volume (%BW) 5.4a 192 3.66 191 0.73 191 2.69 191 40.43 191 7 191 40.09b 
Blood Flow Rate c 191 (%) - 2.4 14.1 15.1 27.8 7 33.6b 
Interstitial Fluid (mL/g tissue) - 0.049 193 0.13 194 0.28 195 0.054 82 0.174 82 0.18d 
Blood Volume (mL/g tissue) - 0.21 191 0.16 191 0.034 196 0.04 191 0.02 191 0.036e 
Capillary Surface Area f 78 (cm2/g) - 250 350 100 70 70 100 
Bile Duct Volume 193 0.4% of liver tissue volume 
Renal Filtrate Volume g 0.25 mL 
Gut Lumen Volume 197 4.5% BW 
Glomerular Filtration Rate 198 10.74 mL/min/kg BW 
Urine Flow Rate 192 200 mL/d/kg BW 
Bile Flow Rate 192 90 mL/d/kg BW 
Feces Flow Rate h 5.63 mL water per day 
Volume calculations were based on density of 1 g/mL.191 
a Plasma volume is 3.12 % of body weight (BW).192 
b Fractional volume and blood flow rate were calculated by subtracting the fraction of other tissues from 1. 
c Expressed as the percent of cardiac output (Qc); Qc = 0.235×BW0.75 L/min, where the unit of BW is kg.191 
d Based on data availability, it was assumed to be the weighted average of brain, heart and spleen fluids.199 
e Calculated on the weighted average of blood volume of the “rest of  body”.191 
f Only the data for liver, kidney and muscle were available; the capillary surface area of other tissues was assumed. In 
kidney, the surface area of glomerular capillary, through which blood filters into filtrate compartment, is 6890 mm 2/g 
kidney.200 The area for exchange between each subcompartment was assumed to be the same as the capillary surface 
area of each tissue, except for the apical membrane of enterocytes and proximal tubules. The microvilli located on 
these two apical membranes could increase the corresponding surface area significantly. Taking this into consideration, 
the surface area of gut lumen would be 4.14 m2/kg BW201 and the area of the apical membrane of proximal tubule 
would be increased by a factor of 5; this was assumed to be the same as the enlargement factor used in describing area 
increasing due to the numerous projections formed on the intestinal wall.201 
g To calculate the volume of the filtrate compartment, we considered the tubular lumen as a cylinder with length of 
5.16 mm202 and diameter of 45 µm203, and there are about 30000 nephrons in adult rats,204 therefore, the volume of the 
filtrate compartment for an adult rat was estimated to be 0.25 mL. 
h We assumed the PFOA was associated with the water content of feces, which was estimated to be 45% of total fecal 
weight.205 Additionally, we used an estimate of fecal production for male Sprague–Dawley rats of 6.88 g dry weight 
per day.206  
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Appendix Table 2. Protein concentrations in different tissues. 
 Ctotal (mg/mL)a 207 Calbumin (µmol/L) CLFABP (µmol/L) Ca2µ (µmol/L) e 
Plasma 67 486b 192   
Liver Fluid  243 208   
Liver Tissue 40  133d 209  
Kidney Fluid  243   
Kidney Tissue 34  2.65 76 110 77 
Gut Fluid  146c   
Gut Tissue 20.6    
Muscle Fluid  146 71   
Muscle Tissue 20.6    
Adipose Fluid  73 71   
Adipose Tissue 20.6    
Rest of Body Fluid  73c   
Rest of Body Tissue 20.6    
a Total protein content of liver, kidney and gut were estimated based on a study that investigated the distribution of heart 
FABP in different organs; in that study, heart FABP concentrations were normalized to both protein content and organ 
weight; based on that information the protein content of each tissue could be determined. For other tissues the same 
protein concentration as that in gut was assumed. 
b Calculated assuming molecular weight of albumin is 65 kg/mol.210 
c Kidney and gut were assumed to have similar albumin levels as liver and the “rest of body” was the same as muscle.  
d Calculated assuming molecular weight of L-FABP is 14 kg/mol.77 




Appendix Table 3. Association constant (Ka) and binding sites (n) of the proteins for PFOA. 
Proteins Ka (M-1) n References 
Albumin 3.10E+03 7.8 Han et al. (2003)39 
LFABP 
1.20E+05 
3 Woodcroft et al. (2010)37 4.00E+04 
1.90E+04 
𝛼2𝜇-globulin 5.00E+02 1 Han et al. (2004)75 
 
 
Appendix Table 4. Effective permeability (Peff) for different tissues and steady-state cell-water concentration 
ratios. 
Tissue Blood Liver Kidney Gut Muscle Adipose Rest of Body 
Peff (m/s) 4.98E-08 5.15E-08 4.38E-08 2.65E-08 2.65E-08 2.65E-08 2.65E-08 
steady-state cell-water concentration ratios 
Hepatocyte to bile 7.28 
Kidney to filtrate 6.19 
Enterocyte to gut lumen 3.75 
 
 
Appendix Table 5. The in vitro net flux for different transporters. 
Transporters Net flux (nmol/mg protein/min) References 
Oat1 0.34 
Weaver et al. (2010)80 Oat3 0.48 
Oatp1a1 0.35 
Ntcp 0.10 




Appendix A.2 PBTK Model Results 
Appendix Table 6. Correlation analysis between parameters and estimated PFOA levels in blood, liver, and 
kidney. 
Parametersa Bloodb Liverb Kidneyb 
Dose - 0.13 0.11 
Blood volume 0.18 - - 
Plasma volume -0.16 - - 
Glomerular filtration rate -0.26 -0.25 - 
Urine flow rate -0.28 -0.25 -0.36 
Capillary surface area of kidney 0.27 0.26 - 
Enlargement factor of apical membrane of proximal tubule - - 0.16 
Effective permeability for blood 0.24 0.23 -0.17 
Effective permeability for liver 0.10 -0.34 0.11 
Effective permeability for kidney - - -0.17 
Steady-state cell-water concentration ratio for kidney 0.25 0.24 0.38 
Albumin concentration in blood 0.29 - - 
Albumin concentration in kidney fluid - - 0.13 
LFABP concentration in liver tissue - 0.33 -0.10 
LFABP concentration in kidney tissue - - 0.12 
Association constant of LFABP - 0.22 - 
Association constant of albumin 0.35 - 0.15 
Renal clearance rate constant -0.16 -0.16 - 
Renal reabsorption rate constant 0.26 0.26 0.39 
Renal efflux rate constant 0.17 0.16 - 
Absorption rate constant of hepatocyte -0.11 0.33 -0.12 
a Only parameters with correlation coefficient ≥ 0.1 and P value < 0.05 are indicated here.  
b the coefficient values are the average of three simulation results at different dose and administration routes (1 






Appendix Table 7. The potential scale reduction factor (PSRF) and multivariate PSRF values of population 
mean and population variance for each selected model parameter. 
Parameters 









PeffB 1.002 1.003 1.038 1.086 
PeffK 1.008 1.025 1.005 1.011 
PeffL 1.010 1.031 1.007 1.017 
CRssL 1.002 1.008 1.003 1.009 
CRssK 1.013 1.039 1.011 1.028 
Pbclear 1.011 1.032 1.003 1.009 
Pbreab 1.020 1.056 1.013 1.035 
Pbabs 1.008 1.023 1.008 1.023 
Pbefflux 1.002 1.005 1.002 1.007 
Ka
Alb 1.005 1.015 1.001 1.003 
Ka
LFABP 1.009 1.026 1.009 1.029 
Model Error 1.001 1.002   

























Appendix B Supporting Information for Chapter 3.0 
 
Appendix Figure 4. The chemical structures of PFAS ligands. 
PFBA: perfluorobutanoic acid; PFPA:  perfluoropentanoic acid; PFHxA: perfluorohexanoic acid; PFHpA: 
perfluoroheptanoic acid; PFOA: linear perfluorooctanoic acid; PFNA: perfluorononanoic acid; 2m-PFOA: 
perfluoro-2-methylheptanoic acid; ADONA: 3H-perfluoro-3-[(3-methoxy-propoxy)propanoic acid]; GenX: 
hexafluoropropylene oxide dimer acid; EEA: perfluoro-3,6-dioxaoctanoic acid; PFBS: perfluorobutane 
sulfonate; PFHxS: perfluorohexane sulfonate; PFOS: perfluorooctane sulfonate; F-53: 6:2 polyfluorinated 
ether sulfonate; F-53B: 6:2 chlorinated polyfluorinated ether sulfonate. All structures were generated from 
the online ChemDraw tool (https://chemdrawdirect.perkinelmer.cloud/js/sample/index.html). 
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Appendix Figure 5. The interactions between human LFABP and PFAS ligands. 
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Entropy Delta G 
PFBA -16.24 -78.09 72.93 -2.03 -16.93 -6.50 
PFPA -16.95 -69.17 68.98 -2.26 -17.20 -2.21 
PFHxA -19.74 -113.98 101.52 -2.55 -18.98 -15.76 
PFHpA -22.53 -76.66 78.90 -2.95 -18.13 -5.11 
PFOA -25.85 -89.69 91.67 -3.24 -19.13 -7.98 
PFNA -28.87 -102.23 101.09 -3.46 -20.55 -12.92 
EEA -25.21 -103.13 97.77 -3.01 -20.41 -13.16 
GenX -23.10 -65.18 67.61 -2.81 -18.61 -4.87 
ADONA -27.34 -108.41 105.77 -3.10 -22.21 -10.88 
2m-PFOA -26.33 -72.53 75.07 -3.20 -19.24 -7.75 
PFBS -23.96 -90.75 90.73 -2.44 -18.51 -7.90 
PFHxS -25.76 -88.32 88.32 -3.02 -18.12 -10.65 
PFOS -31.97 -88.90 90.63 -3.58 -19.82 -13.99 
F-53B -36.59 -84.63 88.79 -3.83 -22.58 -13.68 
F-53 -33.59 -93.55 93.90 -3.80 -21.57 -15.47 
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Appendix Table 9. The mean of ΔGbind and its five energy components calculated based on MM-PBSA for rat 
LFABP. 
 







Entropy Delta G 
PFBA -13.87 -98.03 93.35 -1.86 -14.39 -6.02 
PFPA -15.72 -95.69 93.73 -2.23 -15.07 -4.85 
PFHxA -19.64 -100.33 98.76 -2.61 -16.58 -7.24 
PFHpA -21.70 -102.70 101.94 -2.94 -17.19 -8.21 
PFOA -25.48 -105.33 106.19 -3.21 -17.48 -10.34 
PFNA -28.43 -104.58 108.25 -3.50 -18.03 -10.23 
EEA -24.92 -106.84 107.72 -3.06 -19.59 -7.51 
GenX -20.95 -103.30 104.88 -2.83 -18.47 -3.74 
ADONA -25.80 -108.59 110.51 -3.20 -18.85 -8.23 
2m-PFOA -26.86 -104.63 106.51 -3.17 -18.55 -9.59 
PFBS -20.63 -101.67 99.92 -2.46 -16.66 -8.18 
PFHxS -26.84 -101.73 105.69 -3.07 -18.39 -7.57 
PFOS -30.56 -92.36 98.84 -3.64 -17.76 -9.96 
F-53B -35.21 -107.02 112.68 -3.86 -22.15 -11.26 
F-53 -33.13 -105.26 109.71 -3.78 -21.39 -11.07 
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Appendix C Supporting Information for Chapter 4.0 
In this section, additional information is provided for Chapter 4.0 on ROC-AUC score for 
different machine learning models, hyperparameters for each model, description of the receptors 
(bioassays), structural information of the PFAS in the OECD list and chemical structures for highly 
bioactive PFAS. In addition, the data files including the mean and standard deviation of the AUC 
score of each bioassay task for each machine learning model, the CF data set, the C3F6 data set, 





Appendix Table 10. ROC-AUC scores for different machine learning models. 
Notes: Validation scores for best-performing models for each dataset in bold. GCP: Google Cloud Platform; CRC: 
University of Pittsburgh Center for Research Computing. The ROC-AUC score (Receiver Operating Characteristic-
Area Under the Curve) is used to assess the performance of classification models; and ROC-AUC of 1 is perfect 
classification, whereas an ROC-AUC of 0.5 means a model cannot separate between the two classes at all. 
  
Models 
Mean of ROC-AUC scores 
Machine C3F6 dataset CF dataset 
training validation training validation 
Logistic Regression 0.989 ± 0.002 0.742 ± 0.006 0.920 ± 0.000 0.773 ± 0.023 CPU-8 (GCP) 
Support Vector 
Machine 
0.932 ± 0.037 0.719 ± 0.024 - - CPU-8 (GCP) 
Random Forests 1.000 ± 0.000 0.707 ± 0.028 1.000 ± 0.000 0.777 ± 0.022 CPU-8 (GCP) 
1-hidden-layer 
Multitask Network 
0.999 ± 0.001 0.753 ± 0.027 0.993 ± 0.000 0.821 ± 0.014 CPU-8 (GCP) 
Pyramidal Multitask 
Network 
0.999 ± 0.000 0.772 ± 0.021 0.990 ± 0.001 0.803 ± 0.015 CPU-8 (GCP) 
Graph Convolutional 
Model 
0.992 ± 0.002 0.767 ± 0.024 0.977 ± 0.014 0.813 ± 0.013 GPU-1 (GCP) 
Weave Model 0.982 ± 0.012 0.765 ± 0.016 0.967 ± 0.005 0.765 ± 0.018 GPU-1 (CRC) 
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Appendix Table 11. Summary of the hyperparameters for each machine learning model. 
Model 
Hyperparameters 






Support Vector Machine 
C: 67.7,  
gamma: 0.01 
- 
Random Forests n_estimators: 250 n_estimators: 250 



















Pyramidal Multitask Network  
(2 hidden layer) 
layer_sizes: [2000, 100], 
weight_init_stddevs: [0.02, 0.02], 
bias_init_consts: [1., 1.], 






layer_sizes: [2000, 100], 
weight_init_stddevs: [0.02, 0.02], 
bias_init_consts: [1., 1.], 





























(1) Bold parameters were tuned with Bayesian Optimization. Italic parameters were tuned with Grid Search. For 
other parameters, the default values of each model in DeepChem were used. Finally, underlined parameters for the 
CF dataset were taken from the C3F6 dataset without further optimization, given that the training process is much 
more computationally expensive for the large CF dataset. 
(2) the meaning of each hyperparameter is available in the documentation of the DeepChem package 
(https://www.deepchem.io/docs/deepchem.html). 
 127 
Appendix Table 12. Descriptions for the 26 receptors selected for showing some activity for the chemicals in 
the C3F6 dataset. 




The neuropeptide S receptor (NPSR), which is highly expressed in brain areas 
involving modulation of arousal, stress and anxiety, could be a novel drug 
target for the treatment of sleep and anxiety disorders. This assay is conducted 
to identify NPSR antagonists. 
GLP-1 
The overall aim of this assay is to discover ligands for class B1 GPCRs. 
Specifically, this assay focused on class B1 receptor for glucagon-like peptide-
1 (GLP-1), which is a potential therapeutic target for diabetes and 
neurodegenerative disease. 
ion channel CNG 
The cyclic nucleotide gated (CNG) ion channel was used as a biosensor for 
cAMP induction in this assay. The rationale is that cAMP stimulation will 




Marburg virus could cause Marburg hemorrhagic fever in humans, this assay 




This assay is used to screen small molecules that induce DNA re-replication, 
which can cause the DNA damage response, arrest cell proliferation, and 
trigger apoptosis. 
orthopoxvirus* 
This assay (mCherry Reporter Primary qHTS) is used to screen molecules that 
inhibit Orthopox viruses, which are a genus of viruses including monkeypox 
and variola (the causative agent of smallpox). 
orthopoxvirus* 
Another assay (Venus Reporter Primary qHTS) used to screen molecules that 
inhibit Orthopox viruses. 
other enzymes 
CYP2C9 Cytochromes P450 (CYP) are a group of heme-thiolate monooxygenases that 
oxidize a variety of substances including steroids, fatty acids, and xenobiotics. 
In these assays, three different CYPs (CYP2C9, CYP3A4, and CYP2D6) were 




Aldehyde dehydrogenase 1 (ALDH1A1) is an enzyme that oxidizes a variety 
of endogenous and exogenous aldehydes to the corresponding carboxylic acids 
and is the critical step for retinoic acid metabolism. In this assay, inhibitors of 
ALDH1A1 were identified. 
G9a 
G9a is a histone methyltransferase that is responsible for histone H3 lysine 9 
(H3K9) mono- and di-methylation. It has been recognized as a potential drug 
target for several human diseases, including cancer. The goal of this assay is to 
identify inhibitors of G9a. 
promoter 
ELG1 
As the major subunit of a Replication Factor C-like complex, ELG1 is critical 
to ensure genomic stability during DNA replication. This assay identifies small 
molecules that block ELG1 function. 
ATXN 
Ataxin-2 protein (ATXN2) is encoded by the ATXN2 gene. The mutation in 
ATXN2 could cause Spinocerebellar ataxia type 2 (SCA2) disease. The 
objective of this assay is to identify compounds that inhibit the expression of 
ATXN2. 
protein kinase Plk1 PBD 
Polo-like kinase 1 (Plk1) is a member of a conserved subfamily of serine / 
threonine protein kinases and plays a central role in cell proliferation. Plk1 is a 
potential target for anti-cancer therapy. This assay aimed to identify inhibitors 
that target the Plk1 polo-box domain (PBD). 
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Appendix Table 12 (continued) 
Notes: The description of each receptor is obtained from National Center for Biotechnology Information, PubChem 
Database (https://pubchem.ncbi.nlm.nih.gov/). Those rows in grey indicate receptors that are of less relevance to 




In this assay, a recombinantly expressed fragment of tau, K18 was used to 
identify inhibitors of tau (which is an abundant protein in the axons of neurons 
that stabilizes microtubules) aggregation. 
HTTQ103 
When exon 1 of HTTQ103 (Huntingtin protein containing 103 polyglutamines 
expansion) is expressed, it causes cell death and GFP aggregates. This assay 
screens for small molecules that reduce aggregate formation. 
JMJD2A 
JMJD2A is a jumonji-domain-containing lysine demethylase. In this assay, the 
inhibitors of JMJD2A-tudor domain interactions (which is helpful in probing 
the regulatory pathways of selective demethylation of a given methyllysine 
locus) were identified. 
signaling pathway Gsgsp 
The objective of this assay is to identify molecules with inhibitory activity at 
gsp mutations, which are responsible for McCune-Albright syndrome. 
transcription factor 
ROR gamma 
The goal of this assay is to identify small molecules that inhibit ROR (retinoic 
acid-related orphan receptor) gamma activity. 
VP16 
The goal of this assay is to identify small molecules that inhibit components 
common to both ROR gamma and VP16 transcription factor. 
Nrf2 
Nrf2 is a transcription factor that maintains cellular redox homeostasis and 
protects cells from xenobiotics. This assay is used to screen inhibitors of Nrf2 
function, which could be potential therapeutic targets for improvement in 
cancer treatment. 
Smad3 
TGF-b signaling pathway plays important roles in cellular and development 
pathways. Smad3 is the primary transducer of TGF-b's signals and regulates 
many functions related to TGF-b signaling. The goal of this assay is to identify 
Smad3-small molecule antagonists. 
viability 
HT-1080-NT 
In this assay, a synthetic lethal screen was conducted for chemical probes 
specific for 2HG-producing tumor cells using HT-1080-NT fibrosarcoma cell 
line. 
DT40-hTDP1* 
Human tyrosyl-DNA phosphodiesterase 1 (HTDP1) is a novel repair gene and 
can be used as a new target for anti-cancer drug development. In this assay, 
after exposure to small molecules in the absence of camptothecin, the growth 
kinetics of DT40-hTDP1 cells were evaluated to determine whether the 
molecules can inhibit the TDP1-mediated repair pathway. 
DT40-hTDP1* 
In this assay, after exposure to small molecules in the presence of 
camptothecin, the growth kinetics of DT40-hTDP1 cells were evaluated to 




Appendix Figure 7. The biological activity information of all 3486 PFAS (2688 linear vs 798 nonlinear isomer) 
in the processed OECD dataset for the 23 targets. 
Inside the parentheses, the PubChem AID and the target class are indicated. 
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Appendix Figure 8. The biological activity information of all 3486 PFAS (3119 precursor vs 367 non-
precursor) in the processed OECD dataset for the 23 targets. 
Inside the parentheses, the PubChem AID and the target class are indicated. 
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Appendix Figure 9. The biological activity information of all 3486 PFAS (4 polymer vs 3482 non-polymer) in 
the processed OECD dataset for the 23 targets. 
Inside the parentheses, the PubChem AID and the target class are indicated); Asterisk (*) indicates that there 
is 1 polymer corresponding to that target. 
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Appendix Figure 10. The chemical structures for PFAS that indicate biological activity for at least half of the 
targets investigated in this study. 
The chain length of each individual perfluoroalkyl substructure in the PFAS presented in this figure is no 
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